ID,Description,GeneRatio,BgRatio,RichFactor,FoldEnrichment,zScore,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,15/172,61/3769,0.2459016393442623,5.3883911551658406,7.555267360179953,4.7501411857140676e-8,3.876115207542679e-5,3.6251077469923145e-5,IL4R/OSM/CCL2/VEGFA/CDKN1A/IL1B/LIF/CD36/IL6/MYC/PIM1/FGF2/IL12A/SOCS3/CEBPD,15
R-HSA-6783589,Interleukin-6 family signaling,5/172,8/3769,0.625,13.695494186046512,7.859454232988184,9.361351445835813e-6,0.0038194313899010115,0.0035720946306478756,OSM/LIF/IL6/OSMR/SOCS3,5
R-HSA-1280215,Cytokine Signaling in Immune system,31/172,309/3769,0.10032362459546926,2.198370587792579,4.807084798636869,1.609300954055888e-5,0.004377298595032016,0.00409383576031761,TNFRSF12A/CD44/TNFRSF1A/IL4R/IRAK3/OSM/CCL2/VEGFA/CISH/IL1R1/IL1RL1/EGR1/CDKN1A/MT2A/IRF1/IL1B/LIF/CD36/IL6/MYC/PIM1/FGF2/OSMR/FCGR1A/IL12A/TNIP2/FPR1/ISG20/TUBB6/SOCS3/CEBPD,31
R-HSA-449147,Signaling by Interleukins,23/172,200/3769,0.115,2.5199709302325584,4.829770088294193,2.6967191893689365e-5,0.00491842282360242,0.004599918146428992,TNFRSF1A/IL4R/IRAK3/OSM/CCL2/VEGFA/CISH/IL1R1/IL1RL1/CDKN1A/IL1B/LIF/CD36/IL6/MYC/PIM1/FGF2/OSMR/IL12A/TNIP2/FPR1/SOCS3/CEBPD,23
R-HSA-6783783,Interleukin-10 signaling,8/172,29/3769,0.27586206896551724,6.044907778668804,5.963014716374278,3.0137394752465812e-5,0.00491842282360242,0.004599918146428992,TNFRSF1A/CCL2/IL1R1/IL1B/LIF/IL6/IL12A/FPR1,8
R-HSA-5661231,Metallothioneins bind metals,4/172,6/3769,0.6666666666666666,14.608527131782944,7.294055964047325,5.8504138882564304e-5,0.007956562888028745,0.007441315910501601,MT2A/MT1X/MT1A/MT1M,4
R-HSA-6798695,Neutrophil degranulation,21/172,187/3769,0.11229946524064172,2.4607946772789453,4.480192161384234,8.855994281665978e-5,0.010323559048342054,0.009655031359711028,PLAUR/SLC11A1/SERPINB1/CD44/CRISPLD2/CD93/SIGLEC9/CHI3L1/CD36/TLR2/SLC2A5/FCGR2A/S100A9/CXCR1/CD14/FPR2/FPR1/HSPA6/SERPINA3/PNP/CYFIP1,21
R-HSA-168256,Immune System,55/172,759/3769,0.07246376811594203,1.5878833838894506,3.962582133801853,1.1930596049453602e-4,0.011936230879346116,0.011163270623743463,TNFRSF12A/PLAUR/SLC11A1/SERPINB1/CD44/TNFRSF1A/IL4R/IRAK3/OSM/CRISPLD2/CCL2/VEGFA/CISH/IL1R1/IL1RL1/CR2/EGR1/CDKN1A/MT2A/IRF1/IL1B/CD93/RAC2/LIF/SIGLEC9/CHI3L1/CD36/IL6/MYC/PIM1/TLR2/FGF2/SLC2A5/FCGR2A/OSMR/FCGR1A/S100A9/CXCR1/IFI16/NOS3/IL12A/TNIP2/CD14/FPR2/FPR1/ISG20/HSPA6/TUBB6/SOCS3/SERPINA3/CASP4/PNP/FCGR3A/CEBPD/CYFIP1,55
R-HSA-5660526,Response to metal ions,4/172,7/3769,0.5714285714285714,12.521594684385382,6.671164798606318,1.3164960528690568e-4,0.011936230879346116,0.011163270623743463,MT2A/MT1X/MT1A/MT1M,4
R-HSA-9031628,NGF-stimulated transcription,6/172,24/3769,0.25,5.478197674418604,4.812075376510209,5.60536017290874e-4,0.04573973901093531,0.04277774868798775,F3/EGR1/EGR2/EGR4/FOSL1/ARC,6
R-HSA-5602498,MyD88 deficiency (TLR2/4),4/172,10/3769,0.4,8.765116279069769,5.376024660613524,7.087132137444179e-4,0.05257363476504046,0.0491690985612156,CD36/TLR2/S100A9/CD14,4
R-HSA-8878159,Transcriptional regulation by RUNX3,7/172,35/3769,0.2,4.3825581395348845,4.395837068827871,8.289664690970241e-4,0.05636971989859764,0.052719358780293206,TEAD3/HES1/SPP1/CDKN1A/MYC/RUNX1/TEAD4,7
R-HSA-5603041,IRAK4 deficiency (TLR2/4),4/172,11/3769,0.36363636363636365,7.968287526427061,5.060500459038644,0.001074260354847264,0.06743049611964365,0.06306386698496085,CD36/TLR2/S100A9/CD14,4
R-HSA-168249,Innate Immune System,31/172,389/3769,0.07969151670951156,1.7462635260357506,3.39827184961464,0.0011716701944550906,0.06829163419109671,0.06386923992330382,PLAUR/SLC11A1/SERPINB1/CD44/IRAK3/CRISPLD2/CR2/IL1B/CD93/RAC2/SIGLEC9/CHI3L1/CD36/TLR2/SLC2A5/FCGR2A/FCGR1A/S100A9/CXCR1/IFI16/NOS3/TNIP2/CD14/FPR2/FPR1/HSPA6/SERPINA3/CASP4/PNP/FCGR3A/CYFIP1,31
R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,3/172,6/3769,0.5,10.956395348837209,5.33654407793978,0.0016871810032585237,0.09178264657726369,0.08583903349911787,OSM/LIF/OSMR,3
R-HSA-212436,Generic Transcription Pathway,27/172,337/3769,0.08011869436201781,1.7556241805258437,3.1783126004425593,0.002337099422173898,0.11919207053086879,0.11147349217605762,TEAD3/BBC3/VEGFA/HES1/GADD45A/SPP1/NR4A3/TNFRSF10B/NR4A1/CDK2/CDKN1A/IL6/MYC/THBS1/RUNX1/TNFRSF10D/NPAS4/BDNF/CITED4/POLR2A/CLDN5/SOCS3/TEAD4/ZNF442/NELFE/ZIM2/H4C2,27
R-HSA-2029481,FCGR activation,3/172,7/3769,0.42857142857142855,9.391196013289036,4.858620095178751,0.002853829551737231,0.12564231510962437,0.11750603515799492,FCGR2A/FCGR1A/FCGR3A,3
R-HSA-5686938,Regulation of TLR by endogenous ligand,4/172,14/3769,0.2857142857142857,6.260797342192691,4.311814522182387,0.002925495082209391,0.12564231510962437,0.11750603515799492,CD36/TLR2/S100A9/CD14,4
R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,4/172,14/3769,0.2857142857142857,6.260797342192691,4.311814522182387,0.002925495082209391,0.12564231510962437,0.11750603515799492,VEGFA/CDKN1A/MYC/CITED4,4
R-HSA-1236974,ER-Phagosome pathway,4/172,15/3769,0.26666666666666666,5.843410852713178,4.1095972070255655,0.0038488778202826826,0.15200713225533832,0.1421635331335401,CD36/TLR2/S100A9/CD14,4
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,5/172,24/3769,0.20833333333333334,4.565164728682171,3.830970102569552,0.003911948256571207,0.15200713225533832,0.1421635331335401,EGR2/HELZ2/CD36/ANGPTL4/CEBPD,5
R-HSA-73857,RNA Polymerase II Transcription,27/172,351/3769,0.07692307692307693,1.685599284436494,2.949085313049321,0.0041727204605066254,0.15476999526242757,0.14474748008934463,TEAD3/BBC3/VEGFA/HES1/GADD45A/SPP1/NR4A3/TNFRSF10B/NR4A1/CDK2/CDKN1A/IL6/MYC/THBS1/RUNX1/TNFRSF10D/NPAS4/BDNF/CITED4/POLR2A/CLDN5/SOCS3/TEAD4/ZNF442/NELFE/ZIM2/H4C2,27
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),6/172,36/3769,0.16666666666666666,3.652131782945736,3.4959628355629087,0.005145924278511419,0.18256844396805733,0.17074577125495558,F3/EGR1/EGR2/EGR4/FOSL1/ARC,6
R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,3/172,9/3769,0.3333333333333333,7.304263565891472,4.140102996357439,0.006400217310690708,0.2036322803702894,0.19044556665177995,GADD45A/CDK2/CDKN1A,3
R-HSA-425407,SLC-mediated transmembrane transport,12/172,117/3769,0.10256410256410256,2.2474657125819917,2.9971302403886195,0.006456916902822164,0.2036322803702894,0.19044556665177995,SLC38A5/SLC11A1/CP/SLC12A1/SLCO4A1/SLC1A5/SLC27A6/SLC16A3/SLC5A12/RUNX1/SLC4A5/SLC22A6,12
R-HSA-1236975,Antigen processing-Cross presentation,5/172,27/3769,0.18518518518518517,4.05792420327304,3.4866323749482553,0.006650886848410244,0.2036322803702894,0.19044556665177995,CD36/TLR2/FCGR1A/S100A9/CD14,5
R-HSA-74160,Gene expression (Transcription),29/172,399/3769,0.07268170426065163,1.5926589730139302,2.7373215289187067,0.00673783280636987,0.2036322803702894,0.19044556665177995,TEAD3/BBC3/VEGFA/HES1/GADD45A/SPP1/NR4A3/TNFRSF10B/NR4A1/CDK2/CDKN1A/CD36/IL6/MYC/THBS1/RUNX1/ANGPTL4/TNFRSF10D/NPAS4/BDNF/CITED4/POLR2A/CLDN5/SOCS3/TEAD4/ZNF442/NELFE/ZIM2/H4C2,29
R-HSA-109582,Hemostasis,23/172,296/3769,0.0777027027027027,1.7026830609679444,2.7536098083655474,0.00727436362689985,0.21083485865383036,0.19718172410220203,PLAUR/CD44/SELPLG/VEGFA/F3/TNFRSF10B/SRGN/CDK2/IRF1/RAC2/F12/CD36/THBS1/SLC16A3/ALB/NOS3/TNFRSF10D/TUBB6/THBD/MAFF/SERPINA3/KIF19/ITGB3,23
R-HSA-5260271,Diseases of Immune System,4/172,18/3769,0.2222222222222222,4.869509043927649,3.598056991856257,0.007751281568155528,0.21083485865383036,0.19718172410220203,CD36/TLR2/S100A9/CD14,4
R-HSA-5602358,Diseases associated with the TLR signaling cascade,4/172,18/3769,0.2222222222222222,4.869509043927649,3.598056991856257,0.007751281568155528,0.21083485865383036,0.19718172410220203,CD36/TLR2/S100A9/CD14,4
R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,20/172,253/3769,0.07905138339920949,1.7322364187884915,2.636553597163349,0.010161523373564737,0.2674775184783492,0.25015634790609287,VEGFA/F3/SPP1/EGR1/EGR2/EGR4/MYC/THBS1/FGF2/PTPRK/MST1R/NOS3/FOSL1/BDNF/CDH5/POLR2A/COL4A1/ARC/ITGB3/CYFIP1,20
R-HSA-5620971,Pyroptosis,3/172,11/3769,0.2727272727272727,5.976215644820295,3.6138206782348927,0.011751373226261068,0.29966001726965724,0.280254789113134,IRF1/IL1B/CASP4,3
R-HSA-8953897,Cellular responses to stimuli,21/172,276/3769,0.07608695652173914,1.6672775530839232,2.517741946385509,0.012876395814074343,0.3183981510389292,0.29777948852325037,CCL2/VEGFA/SPP1/CDK2/CDKN1A/MT2A/HELZ2/IL6/MYC/ADM/BAG3/ALB/NOS3/HSPA6/TUBB6/CDH5/MT1X/MT1A/MT1M/ITGB3/H4C2,21
R-HSA-9843745,Adipogenesis,5/172,32/3769,0.15625,3.423873546511628,3.010737214790975,0.01380444577798679,0.33130669867168294,0.3098521111158025,EGR2/HELZ2/CD36/ANGPTL4/CEBPD,5
R-HSA-6803157,Antimicrobial peptides,3/172,12/3769,0.25,5.478197674418604,3.397212686030234,0.015150358333188852,0.34340812221894734,0.32116987694625493,SLC11A1/TLR2/S100A9,3
R-HSA-9759475,Regulation of CDH11 Expression and Function,3/172,12/3769,0.25,5.478197674418604,3.397212686030234,0.015150358333188852,0.34340812221894734,0.32116987694625493,FOXF1/HEYL/ANGPTL4,3
R-HSA-444473,Formyl peptide receptors bind formyl peptides and many other ligands,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,FPR2/FPR1,2
R-HSA-8851708,Signaling by FGFR2 IIIa TM,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,FGF2/POLR2A,2
R-HSA-8939242,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,RUNX1/SOCS3,2
R-HSA-9675126,Diseases of mitotic cell cycle,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,CDK2/CDKN1A,2
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,CDK2/CDKN1A,2
R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,CDKN1A/PIM1,2
R-HSA-9762293,Regulation of CDH11 gene transcription,2/172,5/3769,0.4,8.765116279069769,3.798897798101091,0.018903253504926734,0.3579681195483723,0.33478700551157103,FOXF1/HEYL,2
R-HSA-114608,Platelet degranulation,7/172,62/3769,0.11290322580645161,2.474024756189047,2.5588143693145673,0.021561120764106375,0.3579681195483723,0.33478700551157103,VEGFA/SRGN/CD36/THBS1/ALB/SERPINA3/ITGB3,7
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,4/172,24/3769,0.16666666666666666,3.652131782945736,2.849864828628896,0.02175622354250129,0.3579681195483723,0.33478700551157103,FCGR2A/FCGR1A/FCGR3A/CYFIP1,4
R-HSA-5218859,Regulated Necrosis,4/172,24/3769,0.16666666666666666,3.652131782945736,2.849864828628896,0.02175622354250129,0.3579681195483723,0.33478700551157103,TNFRSF10B/IRF1/IL1B/CASP4,4
R-HSA-2029485,Role of phospholipids in phagocytosis,3/172,14/3769,0.21428571428571427,4.695598006644518,3.0289578017762127,0.023442076037624857,0.3579681195483723,0.33478700551157103,FCGR2A/FCGR1A/FCGR3A,3
R-HSA-69202,Cyclin E associated events during G1/S transition,3/172,14/3769,0.21428571428571427,4.695598006644518,3.0289578017762127,0.023442076037624857,0.3579681195483723,0.33478700551157103,CDK2/CDKN1A/MYC,3
R-HSA-9759476,Regulation of Homotypic Cell-Cell Adhesion,3/172,14/3769,0.21428571428571427,4.695598006644518,3.0289578017762127,0.023442076037624857,0.3579681195483723,0.33478700551157103,FOXF1/HEYL/ANGPTL4,3
R-HSA-9764260,Regulation of Expression and Function of Type II Classical Cadherins,3/172,14/3769,0.21428571428571427,4.695598006644518,3.0289578017762127,0.023442076037624857,0.3579681195483723,0.33478700551157103,FOXF1/HEYL/ANGPTL4,3
R-HSA-9616222,Transcriptional regulation of granulopoiesis,5/172,37/3769,0.13513513513513514,2.961187932118165,2.621191242646,0.024890720340502954,0.3579681195483723,0.33478700551157103,CDK2/CDKN1A/MYC/RUNX1/H4C2,5
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,7/172,64/3769,0.109375,2.3967114825581395,2.46406429658326,0.025246957164001688,0.3579681195483723,0.33478700551157103,VEGFA/SRGN/CD36/THBS1/ALB/SERPINA3/ITGB3,7
R-HSA-112382,Formation of RNA Pol II elongation complex,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-113418,Formation of the Early Elongation Complex,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-167152,Formation of HIV elongation complex in the absence of HIV Tat,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-167158,Formation of the HIV-1 Early Elongation Complex,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-167169,HIV Transcription Elongation,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-167200,Formation of HIV-1 elongation complex containing HIV-1 Tat,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-167246,Tat-mediated elongation of the HIV-1 transcript,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,CDK2/CDKN1A,2
R-HSA-75955,RNA Polymerase II Transcription Elongation,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,POLR2A/NELFE,2
R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,2/172,6/3769,0.3333333333333333,7.304263565891472,3.379032191832234,0.027511289755760827,0.3579681195483723,0.33478700551157103,TEAD3/TEAD4,2
R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",5/172,38/3769,0.13157894736842105,2.8832619339045285,2.551169731509004,0.027637244523955214,0.3579681195483723,0.33478700551157103,SLC11A1/CP/SLC16A3/RUNX1/SLC22A6,5
R-HSA-909733,Interferon alpha/beta signaling,4/172,26/3769,0.15384615384615385,3.371198568872988,2.6527366414955362,0.028526251580002326,0.36370970764502963,0.3401567828207514,EGR1/IRF1/ISG20/SOCS3,4
R-HSA-1643685,Disease,38/172,622/3769,0.06109324758842444,1.3387235474463473,2.0213506643517443,0.03089534036718909,0.38785534984040454,0.3627388140277262,CP/SLC12A1/VEGFA/HES1/IL1R1/CHST3/NR4A1/CDK2/CDKN1A/IL1B/RAC2/F12/CD36/IL6/MYC/PIM1/TLR2/THBS1/FGF2/BCL2A1/FCGR2A/FCGR1A/ADAMTS4/RUNX1/S100A9/ADAMTS9/HEYL/CD14/TUBB6/BDNF/POLR2A/PNP/FCGR3A/NELFE/CEBPD/ITGB3/CYFIP1/H4C2,38
R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,6/172,53/3769,0.11320754716981132,2.4806932865291795,2.3736388470341705,0.03208511496694845,0.38796795405204676,0.36284412627416646,IRAK3/CD36/TLR2/S100A9/TNIP2/CD14,6
R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,6/172,53/3769,0.11320754716981132,2.4806932865291795,2.3736388470341705,0.03208511496694845,0.38796795405204676,0.36284412627416646,IRAK3/CD36/TLR2/S100A9/TNIP2/CD14,6
R-HSA-418990,Adherens junctions interactions,4/172,27/3769,0.14814814814814814,3.246339362618432,2.561266737234012,0.03233066283767056,0.38796795405204676,0.36284412627416646,FOXF1/HEYL/ANGPTL4/CDH5,4
R-HSA-877300,Interferon gamma signaling,5/172,40/3769,0.125,2.739098837209302,2.417728446277321,0.03369056583428067,0.3932865818231596,0.36781833310344525,CD44/MT2A/IRF1/FCGR1A/SOCS3,5
R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,3/172,16/3769,0.1875,4.108648255813954,2.7245309455683895,0.0337378195191436,0.3932865818231596,0.36781833310344525,CDK2/CDKN1A/MYC,3
R-HSA-421270,Cell-cell junction organization,5/172,41/3769,0.12195121951219512,2.6722915484968803,2.354048590805716,0.037003121070861775,0.39353221477098044,0.3680480594800836,FOXF1/HEYL/ANGPTL4/CDH5/CLDN5,5
R-HSA-69563,p53-Dependent G1 DNA Damage Response,2/172,7/3769,0.2857142857142857,6.260797342192691,3.0460753917511836,0.03737427383737026,0.39353221477098044,0.3680480594800836,CDK2/CDKN1A,2
R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,2/172,7/3769,0.2857142857142857,6.260797342192691,3.0460753917511836,0.03737427383737026,0.39353221477098044,0.3680480594800836,CDK2/CDKN1A,2
R-HSA-75158,TRAIL  signaling,2/172,7/3769,0.2857142857142857,6.260797342192691,3.0460753917511836,0.03737427383737026,0.39353221477098044,0.3680480594800836,TNFRSF10B/TNFRSF10D,2
R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,2/172,7/3769,0.2857142857142857,6.260797342192691,3.0460753917511836,0.03737427383737026,0.39353221477098044,0.3680480594800836,GADD45A/CDKN1A,2
R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,6/172,55/3769,0.10909090909090909,2.390486257928118,2.271310704859934,0.03761704994134372,0.39353221477098044,0.3680480594800836,IRAK3/CD36/TLR2/S100A9/TNIP2/CD14,6
R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,6/172,55/3769,0.10909090909090909,2.390486257928118,2.271310704859934,0.03761704994134372,0.39353221477098044,0.3680480594800836,IRAK3/CD36/TLR2/S100A9/TNIP2/CD14,6
R-HSA-8957275,Post-translational protein phosphorylation,6/172,55/3769,0.10909090909090909,2.390486257928118,2.271310704859934,0.03761704994134372,0.39353221477098044,0.3680480594800836,CP/MSLN/STC2/SPP1/IL6/ALB,6
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),3/172,17/3769,0.17647058823529413,3.8669630642954855,2.5903866625803453,0.03962855501760947,0.4093278594223966,0.38282081795825273,F3/F12/THBD,3
R-HSA-166520,Signaling by NTRKs,7/172,71/3769,0.09859154929577464,2.1604159842777593,2.158285410246665,0.041493281306910566,0.4232314693304877,0.39582406509881796,F3/EGR1/EGR2/EGR4/FOSL1/BDNF/ARC,7
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,3/172,18/3769,0.16666666666666666,3.652131782945736,2.466080631062748,0.046004009707500244,0.4356911441905261,0.40747688278912725,CD36/ALB/COL4A1,3
R-HSA-3000170,Syndecan interactions,3/172,18/3769,0.16666666666666666,3.652131782945736,2.466080631062748,0.046004009707500244,0.4356911441905261,0.40747688278912725,THBS1/FGF2/ITGB3,3
R-HSA-4420097,VEGFA-VEGFR2 Pathway,5/172,44/3769,0.11363636363636363,2.4900898520084565,2.173827649418366,0.04810942995183572,0.4356911441905261,0.40747688278912725,VEGFA/NOS3/CDH5/ITGB3/CYFIP1,5
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,TEAD3/TEAD4,2
R-HSA-2892247,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,FGF2/CRIPTO,2
R-HSA-549132,Organic cation/anion/zwitterion transport,2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,RUNX1/SLC22A6,2
R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,NR4A1/CDKN1A,2
R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,TNFRSF10B/TNFRSF10D,2
R-HSA-69615,G1/S DNA Damage Checkpoints,2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,CDK2/CDKN1A,2
R-HSA-982772,Growth hormone receptor signaling,2/172,8/3769,0.25,5.478197674418604,2.772337110519961,0.04836111026072608,0.4356911441905261,0.40747688278912725,CISH/SOCS3,2
R-HSA-375276,Peptide ligand-binding receptors,9/172,105/3769,0.08571428571428572,1.8782392026578074,1.995626157531618,0.04858810554085524,0.4356911441905261,0.40747688278912725,EDN1/CCL2/EDN3/HCRTR2/CXCR1/FPR2/FPR1/OXTR/ACKR1,9
R-HSA-202733,Cell surface interactions at the vascular wall,7/172,74/3769,0.0945945945945946,2.0728315524827154,2.0379317147087495,0.05015758782698822,0.4421548474275944,0.4135220128805547,CD44/SELPLG/TNFRSF10B/SLC16A3/TNFRSF10D/THBD/ITGB3,7
R-HSA-9020702,Interleukin-1 signaling,4/172,31/3769,0.12903225806451613,2.827456864216054,2.2338694279589717,0.050392648052409665,0.4421548474275944,0.4135220128805547,IRAK3/IL1R1/IL1B/TNIP2,4
R-HSA-3700989,Transcriptional Regulation by TP53,8/172,91/3769,0.08791208791208792,1.9263991822131359,1.95597116593451,0.054112232173574,0.46974022823017425,0.4393210338839994,BBC3/GADD45A/TNFRSF10B/CDK2/CDKN1A/TNFRSF10D/POLR2A/NELFE,8
R-HSA-913531,Interferon Signaling,8/172,92/3769,0.08695652173913043,1.9054600606673409,1.9224977886674055,0.05705625370048022,0.478112120809605,0.44715078378091283,CD44/EGR1/MT2A/IRF1/FCGR1A/ISG20/TUBB6/SOCS3,8
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),6/172,61/3769,0.09836065573770492,2.155356462066336,1.9891178016224267,0.057719781167808536,0.478112120809605,0.44715078378091283,CP/MSLN/STC2/SPP1/IL6/ALB,6
R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,3/172,20/3769,0.15,3.286918604651163,2.2421126905227857,0.06016328993185163,0.478112120809605,0.44715078378091283,HES1/MYC/HEYL,3
R-HSA-140534,Caspase activation via Death Receptors in the presence of ligand,2/172,9/3769,0.2222222222222222,4.869509043927649,2.5411637409756187,0.06034993681787906,0.478112120809605,0.44715078378091283,TNFRSF10B/CD14,2
R-HSA-1538133,G0 and Early G1,2/172,9/3769,0.2222222222222222,4.869509043927649,2.5411637409756187,0.06034993681787906,0.478112120809605,0.44715078378091283,CDK2/MYC,2
R-HSA-425410,Metal ion SLC transporters,2/172,9/3769,0.2222222222222222,4.869509043927649,2.5411637409756187,0.06034993681787906,0.478112120809605,0.44715078378091283,SLC11A1/CP,2
R-HSA-8956321,Nucleotide salvage,2/172,9/3769,0.2222222222222222,4.869509043927649,2.5411637409756187,0.06034993681787906,0.478112120809605,0.44715078378091283,TYMP/PNP,2
R-HSA-9703465,Signaling by FLT3 fusion proteins,2/172,9/3769,0.2222222222222222,4.869509043927649,2.5411637409756187,0.06034993681787906,0.478112120809605,0.44715078378091283,CDKN1A/PIM1,2
R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,2/172,9/3769,0.2222222222222222,4.869509043927649,2.5411637409756187,0.06034993681787906,0.478112120809605,0.44715078378091283,CDKN1A/PIM1,2
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,4/172,33/3769,0.12121212121212122,2.6560958421423537,2.089240589087894,0.06112784520937596,0.47961847779664213,0.4485595928825665,NR4A3/THBS1/RUNX1/H4C2,4
R-HSA-9730414,MITF-M-regulated melanocyte development,6/172,63/3769,0.09523809523809523,2.0869324473975635,1.902258671246037,0.06561919997057716,0.505619522911469,0.47287687578794513,EDN1/CDK2/EDN3/CDKN1A/BCL2A1/ZIC1,6
R-HSA-446652,Interleukin-1 family signaling,5/172,48/3769,0.10416666666666667,2.2825823643410854,1.9553544735527877,0.06568096743702907,0.505619522911469,0.47287687578794513,IRAK3/IL1R1/IL1RL1/IL1B/TNIP2,5
R-HSA-187037,Signaling by NTRK1 (TRKA),6/172,64/3769,0.09375,2.054324127906977,1.8600279821883132,0.06979563888160226,0.5175169862163219,0.48400388932770044,F3/EGR1/EGR2/EGR4/FOSL1/ARC,6
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,4/172,35/3769,0.11428571428571428,2.5043189368770764,1.9549526344499926,0.07297572396577519,0.5175169862163219,0.48400388932770044,FCGR2A/FCGR1A/FCGR3A/CYFIP1,4
R-HSA-452723,Transcriptional regulation of pluripotent stem cells,2/172,10/3769,0.2,4.3825581395348845,2.341847220384058,0.07322756268428898,0.5175169862163219,0.48400388932770044,FGF2/CRIPTO,2
R-HSA-9682385,FLT3 signaling in disease,2/172,10/3769,0.2,4.3825581395348845,2.341847220384058,0.07322756268428898,0.5175169862163219,0.48400388932770044,CDKN1A/PIM1,2
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,2/172,10/3769,0.2,4.3825581395348845,2.341847220384058,0.07322756268428898,0.5175169862163219,0.48400388932770044,CDK2/CDKN1A,2
R-HSA-9937080,Developmental Lineage of Multipotent Pancreatic Progenitor Cells,2/172,10/3769,0.2,4.3825581395348845,2.341847220384058,0.07322756268428898,0.5175169862163219,0.48400388932770044,FGF2/HHEX,2
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,12/172,166/3769,0.07228915662650602,1.5840571588680301,1.682777575674456,0.07429682227892283,0.5175169862163219,0.48400388932770044,HES1/NR4A1/CDKN1A/RAC2/MYC/PIM1/FGF2/BCL2A1/HEYL/BDNF/POLR2A/ITGB3,12
R-HSA-194138,Signaling by VEGF,5/172,50/3769,0.1,2.1912790697674422,1.854107352389371,0.07564900045154918,0.5175169862163219,0.48400388932770044,VEGFA/NOS3/CDH5/ITGB3/CYFIP1,5
R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,3/172,22/3769,0.13636363636363635,2.9881078224101474,2.0448378697946077,0.07610543914945911,0.5175169862163219,0.48400388932770044,HES1/MYC/HEYL,3
R-HSA-2644603,Signaling by NOTCH1 in Cancer,3/172,22/3769,0.13636363636363635,2.9881078224101474,2.0448378697946077,0.07610543914945911,0.5175169862163219,0.48400388932770044,HES1/MYC/HEYL,3
R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,3/172,22/3769,0.13636363636363635,2.9881078224101474,2.0448378697946077,0.07610543914945911,0.5175169862163219,0.48400388932770044,HES1/MYC/HEYL,3
R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,3/172,22/3769,0.13636363636363635,2.9881078224101474,2.0448378697946077,0.07610543914945911,0.5175169862163219,0.48400388932770044,HES1/MYC/HEYL,3
R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,3/172,22/3769,0.13636363636363635,2.9881078224101474,2.0448378697946077,0.07610543914945911,0.5175169862163219,0.48400388932770044,HES1/MYC/HEYL,3
R-HSA-9664323,FCGR3A-mediated IL10 synthesis,3/172,22/3769,0.13636363636363635,2.9881078224101474,2.0448378697946077,0.07610543914945911,0.5175169862163219,0.48400388932770044,FCGR2A/FCGR1A/FCGR3A,3
R-HSA-9711123,Cellular response to chemical stress,5/172,51/3769,0.09803921568627451,2.148312813497492,1.805261240756753,0.0809246120430941,0.5457395324559073,0.510398814538871,CCL2/CDKN1A/HELZ2/MYC/ALB,5
R-HSA-8878171,Transcriptional regulation by RUNX1,6/172,67/3769,0.08955223880597014,1.9623394654633808,1.7377885935575992,0.08322870363805676,0.5529472444166672,0.5171397732225022,NR4A3/THBS1/RUNX1/CLDN5/SOCS3/H4C2,6
R-HSA-5083635,Defective B3GALTL causes PpS,3/172,23/3769,0.13043478260869565,2.8581900910010107,1.954427761549541,0.08470392837265123,0.5529472444166672,0.5171397732225022,THBS1/ADAMTS4/ADAMTS9,3
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,3/172,23/3769,0.13043478260869565,2.8581900910010107,1.954427761549541,0.08470392837265123,0.5529472444166672,0.5171397732225022,THBS1/ADAMTS4/ADAMTS9,3
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,3/172,23/3769,0.13043478260869565,2.8581900910010107,1.954427761549541,0.08470392837265123,0.5529472444166672,0.5171397732225022,BBC3/TNFRSF10B/TNFRSF10D,3
R-HSA-2219528,PI3K/AKT Signaling in Cancer,5/172,52/3769,0.09615384615384616,2.106999105545617,1.7575274340405627,0.08639208217025238,0.5539169805112154,0.518046711649421,NR4A1/CDKN1A/RAC2/FGF2/BDNF,5
R-HSA-9855142,Cellular responses to mechanical stimuli,5/172,52/3769,0.09615384615384616,2.106999105545617,1.7575274340405627,0.08639208217025238,0.5539169805112154,0.518046711649421,SPP1/ADM/NOS3/CDH5/ITGB3,5
R-HSA-674695,RNA Polymerase II Pre-transcription Events,2/172,11/3769,0.18181818181818182,3.9841437632135306,2.1671408974311426,0.08688893811940633,0.5539169805112154,0.518046711649421,POLR2A/NELFE,2
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),4/172,38/3769,0.10526315789473684,2.3066095471236228,1.770004834437151,0.09275756371395974,0.5788616544769237,0.5413760313412922,CDK2/CDKN1A/IL6/H4C2,4
R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,6/172,69/3769,0.08695652173913043,1.9054600606673409,1.6597490683003224,0.09292999600058457,0.5788616544769237,0.5413760313412922,IRAK3/CD36/TLR2/S100A9/TNIP2/CD14,6
R-HSA-5357801,Programmed Cell Death,6/172,69/3769,0.08695652173913043,1.9054600606673409,1.6597490683003224,0.09292999600058457,0.5788616544769237,0.5413760313412922,BBC3/TNFRSF10B/IRF1/IL1B/CD14/CASP4,6
R-HSA-1222556,ROS and RNS production in phagocytes,3/172,24/3769,0.125,2.739098837209302,1.8687595546882394,0.09369645763410114,0.5792144653744434,0.5417059950934875,SLC11A1/RAC2/NOS3,3
R-HSA-167172,Transcription of the HIV genome,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,POLR2A/NELFE,2
R-HSA-1839126,FGFR2 mutant receptor activation,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,FGF2/POLR2A,2
R-HSA-69231,Cyclin D associated events in G1,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,CDK2/CDKN1A,2
R-HSA-69236,G1 Phase,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,CDK2/CDKN1A,2
R-HSA-9707564,Cytoprotection by HMOX1,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,HELZ2/ALB,2
R-HSA-9768919,NPAS4 regulates expression of target genes,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,NPAS4/BDNF,2
R-HSA-9856532,Mechanical load activates signaling by PIEZO1 and integrins in osteocytes,2/172,12/3769,0.16666666666666666,3.652131782945736,2.0119379252763716,0.1012366540766498,0.5943101419175989,0.5558241136355252,SPP1/ITGB3,2
R-HSA-9614085,FOXO-mediated transcription,3/172,25/3769,0.12,2.6295348837209302,1.7873730189826162,0.10306379385615087,0.6007146841901365,0.5618139138775141,BBC3/GADD45A/CDKN1A,3
R-HSA-446728,Cell junction organization,5/172,55/3769,0.09090909090909091,1.9920718816067653,1.6205147457131275,0.10392042475443794,0.6014118198554707,0.5624659047925905,FOXF1/HEYL/ANGPTL4/CDH5/CLDN5,5
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,3/172,26/3769,0.11538461538461539,2.5283989266547406,1.7098693836874757,0.11278608197912683,0.6449201606715026,0.6031567550139826,EDN1/EDN3/ZIC1,3
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,4/172,41/3769,0.0975609756097561,2.1378332387975045,1.601703204665909,0.1148082010412729,0.6449201606715026,0.6031567550139826,IL6/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-9664433,Leishmania parasite growth and survival,4/172,41/3769,0.0975609756097561,2.1378332387975045,1.601703204665909,0.1148082010412729,0.6449201606715026,0.6031567550139826,IL6/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-5218920,VEGFR2 mediated vascular permeability,2/172,13/3769,0.15384615384615385,3.371198568872988,1.8725191167093798,0.11618047012096921,0.6449201606715026,0.6031567550139826,NOS3/CDH5,2
R-HSA-5357769,Caspase activation via extrinsic apoptotic signalling pathway,2/172,13/3769,0.15384615384615385,3.371198568872988,1.8725191167093798,0.11618047012096921,0.6449201606715026,0.6031567550139826,TNFRSF10B/CD14,2
R-HSA-6796648,TP53 Regulates Transcription of DNA Repair Genes,2/172,13/3769,0.15384615384615385,3.371198568872988,1.8725191167093798,0.11618047012096921,0.6449201606715026,0.6031567550139826,POLR2A/NELFE,2
R-HSA-1257604,PIP3 activates AKT signaling,7/172,91/3769,0.07692307692307693,1.685599284436494,1.4475535573547054,0.11973714839152118,0.6601723857262248,0.6174212843801767,IL1RL1/EGR1/NR4A1/CDKN1A/RAC2/FGF2/BDNF,7
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,3/172,27/3769,0.1111111111111111,2.4347545219638245,1.635901099519768,0.12284300937180881,0.6650734512894872,0.6220049692787387,CDK2/CDKN1A/H4C2,3
R-HSA-9755511,KEAP1-NFE2L2 pathway,3/172,27/3769,0.1111111111111111,2.4347545219638245,1.635901099519768,0.12284300937180881,0.6650734512894872,0.6220049692787387,CCL2/CDKN1A/MYC,3
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,5/172,58/3769,0.08620689655172414,1.8890336808340018,1.4918878794953803,0.12307119012832424,0.6650734512894872,0.6220049692787387,SLC38A5/SLC12A1/SLC1A5/SLC5A12/SLC4A5,5
R-HSA-216083,Integrin cell surface interactions,5/172,59/3769,0.0847457627118644,1.8570161608198659,1.4506996763010425,0.12979781901119444,0.6923731606650231,0.647536818217417,CD44/SPP1/THBS1/COL4A1/ITGB3,5
R-HSA-9758941,Gastrulation,4/172,43/3769,0.09302325581395349,2.0383991346673875,1.4973611871363095,0.13067201427100622,0.6923731606650231,0.647536818217417,FOXF1/FGF2/ZIC1/TEAD4,4
R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,2/172,14/3769,0.14285714285714285,3.1303986710963456,1.7461010813700386,0.13163686913486009,0.6923731606650231,0.647536818217417,RAC2/S100A9,2
R-HSA-9839373,Signaling by TGFBR3,2/172,14/3769,0.14285714285714285,3.1303986710963456,1.7461010813700386,0.13163686913486009,0.6923731606650231,0.647536818217417,INHA/FGF2,2
R-HSA-186797,Signaling by PDGF,3/172,28/3769,0.10714285714285714,2.347799003322259,1.5651636173664853,0.13321395370638311,0.6923731606650231,0.647536818217417,SPP1/THBS1/COL4A1,3
R-HSA-1980143,Signaling by NOTCH1,3/172,28/3769,0.10714285714285714,2.347799003322259,1.5651636173664853,0.13321395370638311,0.6923731606650231,0.647536818217417,HES1/MYC/HEYL,3
R-HSA-9658195,Leishmania infection,6/172,77/3769,0.07792207792207792,1.7074901842343702,1.3714639200021057,0.13744893923213058,0.7053983296441418,0.6597185100516032,IL1B/IL6/FCGR2A/FCGR1A/FCGR3A/CYFIP1,6
R-HSA-9824443,Parasitic Infection Pathways,6/172,77/3769,0.07792207792207792,1.7074901842343702,1.3714639200021057,0.13744893923213058,0.7053983296441418,0.6597185100516032,IL1B/IL6/FCGR2A/FCGR1A/FCGR3A/CYFIP1,6
R-HSA-9860931,Response of endothelial cells to shear stress,4/172,44/3769,0.09090909090909091,1.9920718816067653,1.447290768097286,0.1389282727029233,0.7085341907849088,0.6626513007211801,ADM/NOS3/CDH5/ITGB3,4
R-HSA-9013423,RAC3 GTPase cycle,4/172,45/3769,0.08888888888888889,1.9478036175710596,1.3985217801098415,0.14738903875080325,0.7385482705260058,0.690721744235493,SLC1A5/ARAP3/VANGL1/CYFIP1,4
R-HSA-3371453,Regulation of HSF1-mediated heat shock response,2/172,15/3769,0.13333333333333333,2.921705426356589,1.6305524129667697,0.1475286373722291,0.7385482705260058,0.690721744235493,BAG3/HSPA6,2
R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,2/172,15/3769,0.13333333333333333,2.921705426356589,1.6305524129667697,0.1475286373722291,0.7385482705260058,0.690721744235493,HES1/HEYL,2
R-HSA-5655253,Signaling by FGFR2 in disease,2/172,16/3769,0.125,2.739098837209302,1.5242086622431692,0.16378446849409856,0.7452497055915802,0.6969892112408355,FGF2/POLR2A,2
R-HSA-8956319,Nucleotide catabolism,2/172,16/3769,0.125,2.739098837209302,1.5242086622431692,0.16378446849409856,0.7452497055915802,0.6969892112408355,TYMP/PNP,2
R-HSA-9634815,Transcriptional Regulation by NPAS4,2/172,16/3769,0.125,2.739098837209302,1.5242086622431692,0.16378446849409856,0.7452497055915802,0.6969892112408355,NPAS4/BDNF,2
R-HSA-9837999,Mitochondrial protein degradation,2/172,16/3769,0.125,2.739098837209302,1.5242086622431692,0.16378446849409856,0.7452497055915802,0.6969892112408355,PDK1/MRPL12,2
R-HSA-157579,Telomere Maintenance,3/172,31/3769,0.0967741935483871,2.1205926481620407,1.3698039647018532,0.16600270731005348,0.7452497055915802,0.6969892112408355,CDK2/POLR2A/H4C2,3
R-HSA-1266738,Developmental Biology,30/172,551/3769,0.0544464609800363,1.1930739036846325,1.0723975389529004,0.1673891273559124,0.7452497055915802,0.6969892112408355,EDN1/FOXF1/HES1/EGR2/CDK2/EDN3/CDKN1A/HELZ2/DSC2/CD36/MYC/FGF2/BCL2A1/HHEX/ZIC1/RUNX1/ANGPTL4/GDNF/EFNA1/TUBB6/POLR2A/LIMK2/COL4A1/GJB3/TEAD4/SPINK9/CEBPD/CRIPTO/ITGB3/H4C2,30
R-HSA-168898,Toll-like Receptor Cascades,6/172,82/3769,0.07317073170731707,1.603374929098128,1.2078334970101248,0.16954098648792434,0.7452497055915802,0.6969892112408355,IRAK3/CD36/TLR2/S100A9/TNIP2/CD14,6
R-HSA-3000171,Non-integrin membrane-ECM interactions,4/172,48/3769,0.08333333333333333,1.826065891472868,1.2593745877448308,0.17390617236793623,0.7452497055915802,0.6969892112408355,THBS1/FGF2/COL4A1/ITGB3,4
R-HSA-9013406,RHOQ GTPase cycle,3/172,32/3769,0.09375,2.054324127906977,1.309595087132301,0.17742165626368533,0.7452497055915802,0.6969892112408355,SLC1A5/TRIP10/VANGL1,3
R-HSA-190861,Gap junction assembly,2/172,17/3769,0.11764705882352941,2.5779753761969904,1.4257478302690818,0.18033859029096383,0.7452497055915802,0.6969892112408355,TUBB6/GJB3,2
R-HSA-425397,"Transport of vitamins, nucleosides, and related molecules",2/172,17/3769,0.11764705882352941,2.5779753761969904,1.4257478302690818,0.18033859029096383,0.7452497055915802,0.6969892112408355,SLCO4A1/SLC27A6,2
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,2/172,17/3769,0.11764705882352941,2.5779753761969904,1.4257478302690818,0.18033859029096383,0.7452497055915802,0.6969892112408355,CDKN1A/TUBB6,2
R-HSA-9013407,RHOH GTPase cycle,2/172,17/3769,0.11764705882352941,2.5779753761969904,1.4257478302690818,0.18033859029096383,0.7452497055915802,0.6969892112408355,SLC1A5/VANGL1,2
R-HSA-69206,G1/S Transition,3/172,33/3769,0.09090909090909091,1.9920718816067653,1.2515440167185032,0.18905103736911633,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/MYC,3
R-HSA-69242,S Phase,3/172,33/3769,0.09090909090909091,1.9920718816067653,1.2515440167185032,0.18905103736911633,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/MYC,3
R-HSA-8963899,Plasma lipoprotein remodeling,2/172,18/3769,0.1111111111111111,2.4347545219638245,1.3341042702692398,0.19713041286389657,0.7452497055915802,0.6969892112408355,ALB/ANGPTL4,2
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,5/172,68/3769,0.07352941176470588,1.611234610123119,1.1121216691867364,0.19714219894732182,0.7452497055915802,0.6969892112408355,CDK2/IRF1/TUBB6/MAFF/KIF19,5
R-HSA-1989781,PPARA activates gene expression,3/172,34/3769,0.08823529411764706,1.9334815321477428,1.19549933095961,0.20087070027667128,0.7452497055915802,0.6969892112408355,HELZ2/CD36/ANGPTL4,3
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,3/172,34/3769,0.08823529411764706,1.9334815321477428,1.19549933095961,0.20087070027667128,0.7452497055915802,0.6969892112408355,THBS1/ADAMTS4/ADAMTS9,3
R-HSA-400206,Regulation of lipid metabolism by PPARalpha,3/172,34/3769,0.08823529411764706,1.9334815321477428,1.19549933095961,0.20087070027667128,0.7452497055915802,0.6969892112408355,HELZ2/CD36/ANGPTL4,3
R-HSA-9856530,High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,3/172,34/3769,0.08823529411764706,1.9334815321477428,1.19549933095961,0.20087070027667128,0.7452497055915802,0.6969892112408355,ADM/NOS3/CDH5,3
R-HSA-5173105,O-linked glycosylation,4/172,51/3769,0.0784313725490196,1.7186502507979937,1.1297892248317851,0.20192493307151196,0.7452497055915802,0.6969892112408355,GALNT5/THBS1/ADAMTS4/ADAMTS9,4
R-HSA-1433617,Regulation of signaling by NODAL,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CRIPTO,1
R-HSA-190377,FGFR2b ligand binding and activation,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-198323,AKT phosphorylates targets in the cytosol,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CDKN1A,1
R-HSA-2160916,Hyaluronan uptake and degradation,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CD44,1
R-HSA-3000471,Scavenging by Class B Receptors,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CD36,1
R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,ITGB3,1
R-HSA-389397,Orexin and neuropeptides FF and QRFP bind to their respective receptors,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,HCRTR2,1
R-HSA-427601,Multifunctional anion exchangers,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,SLC5A12,1
R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,MYC,1
R-HSA-549127,Organic cation transport,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,RUNX1,1
R-HSA-72165,mRNA Splicing - Minor Pathway,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-75205,Dissolution of Fibrin Clot,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,PLAUR,1
R-HSA-877312,Regulation of IFNG signaling,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,SOCS3,1
R-HSA-8866907,Activation of the TFAP2 (AP-2) family of transcription factors,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CITED4,1
R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,VEGFA,1
R-HSA-8877330,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,RUNX1,1
R-HSA-8934593,Regulation of RUNX1 Expression and Activity,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,RUNX1,1
R-HSA-8941855,RUNX3 regulates CDKN1A transcription,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CDKN1A,1
R-HSA-937041,IKK complex recruitment mediated by RIP1,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,CD14,1
R-HSA-9614657,FOXO-mediated transcription of cell death genes,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,BBC3,1
R-HSA-9768759,Regulation of NPAS4 gene expression,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,NPAS4,1
R-HSA-9796292,Formation of axial mesoderm,1/172,5/3769,0.2,4.3825581395348845,1.654835833284827,0.20838072980983646,0.7452497055915802,0.6969892112408355,TEAD4,1
R-HSA-76002,"Platelet activation, signaling and aggregation",8/172,125/3769,0.064,1.4024186046511629,1.0004452459180138,0.20942855105628208,0.7452497055915802,0.6969892112408355,VEGFA/SRGN/RAC2/CD36/THBS1/ALB/SERPINA3/ITGB3,8
R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,3/172,35/3769,0.08571428571428572,1.8782392026578074,1.1413244896573664,0.2128608543058178,0.7452497055915802,0.6969892112408355,EGR2/POLR2A/H4C2,3
R-HSA-5619507,Activation of HOX genes during differentiation,3/172,35/3769,0.08571428571428572,1.8782392026578074,1.1413244896573664,0.2128608543058178,0.7452497055915802,0.6969892112408355,EGR2/POLR2A/H4C2,3
R-HSA-73886,Chromosome Maintenance,3/172,35/3769,0.08571428571428572,1.8782392026578074,1.1413244896573664,0.2128608543058178,0.7452497055915802,0.6969892112408355,CDK2/POLR2A/H4C2,3
R-HSA-8878166,Transcriptional regulation by RUNX2,3/172,35/3769,0.08571428571428572,1.8782392026578074,1.1413244896573664,0.2128608543058178,0.7452497055915802,0.6969892112408355,HES1/CDKN1A/RUNX1,3
R-HSA-352230,Amino acid transport across the plasma membrane,2/172,19/3769,0.10526315789473684,2.3066095471236228,1.248407719300931,0.21410419710035306,0.7452497055915802,0.6969892112408355,SLC38A5/SLC1A5,2
R-HSA-1500931,Cell-Cell communication,5/172,71/3769,0.07042253521126761,1.5431542744841142,1.010225610483814,0.22189379749882707,0.7452497055915802,0.6969892112408355,FOXF1/HEYL/ANGPTL4/CDH5/CLDN5,5
R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,3/172,36/3769,0.08333333333333333,1.826065891472868,1.0888959873282353,0.22500212347030757,0.7452497055915802,0.6969892112408355,PLAUR/MSLN/LYPD8,3
R-HSA-1474228,Degradation of the extracellular matrix,5/172,72/3769,0.06944444444444445,1.5217215762273903,0.977304215898301,0.23035030579374832,0.7452497055915802,0.6969892112408355,CD44/SPP1/ADAMTS4/ADAMTS9/COL4A1,5
R-HSA-453274,Mitotic G2-G2/M phases,4/172,54/3769,0.07407407407407407,1.623169681309216,1.0084938129468808,0.2311812853940725,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/PLK4/TUBB6,4
R-HSA-69275,G2/M Transition,4/172,54/3769,0.07407407407407407,1.623169681309216,1.0084938129468808,0.2311812853940725,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/PLK4/TUBB6,4
R-HSA-9664407,Parasite infection,2/172,20/3769,0.1,2.1912790697674422,1.1679392151725405,0.2312087423412977,0.7452497055915802,0.6969892112408355,FCGR3A/CYFIP1,2
R-HSA-9664417,Leishmania phagocytosis,2/172,20/3769,0.1,2.1912790697674422,1.1679392151725405,0.2312087423412977,0.7452497055915802,0.6969892112408355,FCGR3A/CYFIP1,2
R-HSA-9664422,FCGR3A-mediated phagocytosis,2/172,20/3769,0.1,2.1912790697674422,1.1679392151725405,0.2312087423412977,0.7452497055915802,0.6969892112408355,FCGR3A/CYFIP1,2
R-HSA-1236978,Cross-presentation of soluble exogenous antigens (endosomes),1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,FCGR1A,1
R-HSA-1474151,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,NOS3,1
R-HSA-159418,Recycling of bile acids and salts,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,ALB,1
R-HSA-167160,RNA Pol II CTD phosphorylation and interaction with CE during HIV infection,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-1839122,Signaling by activated point mutants of FGFR1,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-194313,VEGF ligand-receptor interactions,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,VEGFA,1
R-HSA-195399,VEGF binds to VEGFR leading to receptor dimerization,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,VEGFA,1
R-HSA-2022377,Metabolism of Angiotensinogen to Angiotensins,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,ENPEP,1
R-HSA-204174,Regulation of pyruvate dehydrogenase (PDH) complex,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,PDK1,1
R-HSA-209952,Peptide hormone biosynthesis,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,INHA,1
R-HSA-210990,PECAM1 interactions,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,ITGB3,1
R-HSA-2197563,NOTCH2 intracellular domain regulates transcription,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,HES1,1
R-HSA-3371378,Regulation by c-FLIP,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,TNFRSF10B,1
R-HSA-372708,p130Cas linkage to MAPK signaling for integrins,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,ITGB3,1
R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,CCL2,1
R-HSA-381042,PERK regulates gene expression,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,CCL2,1
R-HSA-419812,Calcitonin-like ligand receptors,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,ADM,1
R-HSA-448706,Interleukin-1 processing,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,IL1B,1
R-HSA-5218900,CASP8 activity is inhibited,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,TNFRSF10B,1
R-HSA-622323,Presynaptic nicotinic acetylcholine receptors,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,CHRNB3,1
R-HSA-629597,Highly calcium permeable nicotinic acetylcholine receptors,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,CHRNB3,1
R-HSA-6803529,FGFR2 alternative splicing,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-69017,CDK-mediated phosphorylation and removal of Cdc6,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-69416,Dimerization of procaspase-8,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,TNFRSF10B,1
R-HSA-72086,mRNA Capping,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-74217,Purine salvage,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,PNP,1
R-HSA-77075,RNA Pol II CTD phosphorylation and interaction with CE,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-804914,Transport of fatty acids,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,SLC27A6,1
R-HSA-879518,Transport of organic anions,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,SLCO4A1,1
R-HSA-8949275,RUNX3 Regulates Immune Response and Cell Migration,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,SPP1,1
R-HSA-8951936,RUNX3 regulates p14-ARF,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,RUNX1,1
R-HSA-9755088,Ribavirin ADME,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,PNP,1
R-HSA-9762292,Regulation of CDH11 function,1/172,6/3769,0.16666666666666666,3.652131782945736,1.4215203057246886,0.2445546178206519,0.7452497055915802,0.6969892112408355,ANGPTL4,1
R-HSA-453279,Mitotic G1 phase and G1/S transition,3/172,38/3769,0.07894736842105263,1.729957160342717,0.9888399373652983,0.24966285350194706,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/MYC,3
R-HSA-9006936,Signaling by TGFB family members,4/172,56/3769,0.07142857142857142,1.5651993355481728,0.9317140253905707,0.2512420725278964,0.7452497055915802,0.6969892112408355,INHA/MYC/FGF2/ITGB3,4
R-HSA-9018519,Estrogen-dependent gene expression,4/172,56/3769,0.07142857142857142,1.5651993355481728,0.9317140253905707,0.2512420725278964,0.7452497055915802,0.6969892112408355,MYC/RUNX1/POLR2A/H4C2,4
R-HSA-157118,Signaling by NOTCH,5/172,75/3769,0.06666666666666667,1.4608527131782945,0.8814420932712774,0.25625348670445386,0.7452497055915802,0.6969892112408355,HES1/MYC/RUNX1/HEYL/H4C2,5
R-HSA-3781865,Diseases of glycosylation,4/172,57/3769,0.07017543859649122,1.5377396980824152,0.8944477886097444,0.26141027760306645,0.7452497055915802,0.6969892112408355,CHST3/THBS1/ADAMTS4/ADAMTS9,4
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",4/172,57/3769,0.07017543859649122,1.5377396980824152,0.8944477886097444,0.26141027760306645,0.7452497055915802,0.6969892112408355,IL1RL1/RAC2/FGF2/BDNF,4
R-HSA-1226099,Signaling by FGFR in disease,2/172,22/3769,0.09090909090909091,1.9920718816067653,1.0203803486918726,0.2656262574982845,0.7452497055915802,0.6969892112408355,FGF2/POLR2A,2
R-HSA-162599,Late Phase of HIV Life Cycle,2/172,22/3769,0.09090909090909091,1.9920718816067653,1.0203803486918726,0.2656262574982845,0.7452497055915802,0.6969892112408355,POLR2A/NELFE,2
R-HSA-3371556,Cellular response to heat stress,2/172,22/3769,0.09090909090909091,1.9920718816067653,1.0203803486918726,0.2656262574982845,0.7452497055915802,0.6969892112408355,BAG3/HSPA6,2
R-HSA-380108,Chemokine receptors bind chemokines,2/172,22/3769,0.09090909090909091,1.9920718816067653,1.0203803486918726,0.2656262574982845,0.7452497055915802,0.6969892112408355,CCL2/CXCR1,2
R-HSA-9012852,Signaling by NOTCH3,2/172,22/3769,0.09090909090909091,1.9920718816067653,1.0203803486918726,0.2656262574982845,0.7452497055915802,0.6969892112408355,HES1/HEYL,2
R-HSA-9759194,Nuclear events mediated by NFE2L2,2/172,22/3769,0.09090909090909091,1.9920718816067653,1.0203803486918726,0.2656262574982845,0.7452497055915802,0.6969892112408355,CCL2/MYC,2
R-HSA-2559583,Cellular Senescence,4/172,58/3769,0.06896551724137931,1.511226944667201,0.8578902001833847,0.2716576174160106,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/IL6/H4C2,4
R-HSA-9006925,Intracellular signaling by second messengers,7/172,116/3769,0.0603448275862069,1.3223235765838013,0.7709845648859561,0.2774445142543057,0.7452497055915802,0.6969892112408355,IL1RL1/EGR1/NR4A1/CDKN1A/RAC2/FGF2/BDNF,7
R-HSA-1236973,Cross-presentation of particulate exogenous antigens (phagosomes),1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,CD36,1
R-HSA-1362277,Transcription of E2F targets under negative control by DREAM complex,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,MYC,1
R-HSA-1482925,Acyl chain remodelling of PG,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,PLA2G5,1
R-HSA-1502540,Signaling by Activin,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,INHA,1
R-HSA-168325,Viral Messenger RNA Synthesis,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-189445,Metabolism of porphyrins,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,ALB,1
R-HSA-189483,Heme degradation,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,ALB,1
R-HSA-190322,FGFR4 ligand binding and activation,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-190373,FGFR1c ligand binding and activation,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-190375,FGFR2c ligand binding and activation,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-202131,Metabolism of nitric oxide: NOS3 activation and regulation,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,NOS3,1
R-HSA-203615,eNOS activation,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,NOS3,1
R-HSA-3232118,SUMOylation of transcription factors,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,HIC1,1
R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-5654228,Phospholipase C-mediated cascade; FGFR4,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5658623,FGFRL1 modulation of FGFR1 signaling,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-6781823,Formation of TC-NER Pre-Incision Complex,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-73621,Pyrimidine catabolism,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,TYMP,1
R-HSA-8853884,Transcriptional Regulation by VENTX,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,IL6,1
R-HSA-8964058,HDL remodeling,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,ALB,1
R-HSA-912694,Regulation of IFNA/IFNB signaling,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,SOCS3,1
R-HSA-9651496,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,F12,1
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,SOCS3,1
R-HSA-9931510,Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes,1/172,7/3769,0.14285714285714285,3.1303986710963456,1.2335306883236163,0.2790846751511987,0.7452497055915802,0.6969892112408355,LOC102724428,1
R-HSA-190828,Gap junction trafficking,2/172,23/3769,0.08695652173913043,1.9054600606673409,0.9523548145654271,0.28285695551024936,0.7452497055915802,0.6969892112408355,TUBB6/GJB3,2
R-HSA-9670095,Inhibition of DNA recombination at telomere,2/172,23/3769,0.08695652173913043,1.9054600606673409,0.9523548145654271,0.28285695551024936,0.7452497055915802,0.6969892112408355,POLR2A/H4C2,2
R-HSA-9830369,Kidney development,2/172,23/3769,0.08695652173913043,1.9054600606673409,0.9523548145654271,0.28285695551024936,0.7452497055915802,0.6969892112408355,FGF2/GDNF,2
R-HSA-983169,Class I MHC mediated antigen processing & presentation,6/172,98/3769,0.061224489795918366,1.3415994304698624,0.7491821738178603,0.28885388259978345,0.7452497055915802,0.6969892112408355,CD36/TLR2/FCGR1A/S100A9/CD14/SOCS3,6
R-HSA-2262752,Cellular responses to stress,12/172,218/3769,0.05504587155963303,1.2062086622573076,0.6858186121849559,0.29070325412418424,0.7452497055915802,0.6969892112408355,CCL2/VEGFA/CDK2/CDKN1A/HELZ2/IL6/MYC/BAG3/ALB/HSPA6/TUBB6/H4C2,12
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),10/172,179/3769,0.055865921787709494,1.2241782512667272,0.6719271968088815,0.2992072390623699,0.7452497055915802,0.6969892112408355,EDN1/CCL2/EDN3/HCRTR2/CXCR1/FPR2/FPR1/GPR4/OXTR/ACKR1,10
R-HSA-500792,GPCR ligand binding,13/172,240/3769,0.05416666666666667,1.1869428294573643,0.6543921107556988,0.299309752875786,0.7452497055915802,0.6969892112408355,WNT8A/EDN1/CCL2/EDN3/ADGRE2/HCRTR2/ADM/CXCR1/FPR2/FPR1/GPR4/OXTR/ACKR1,13
R-HSA-9856651,MITF-M-dependent gene expression,3/172,42/3769,0.07142857142857142,1.5651993355481728,0.8053711032469313,0.30000086478606286,0.7452497055915802,0.6969892112408355,CDK2/CDKN1A/BCL2A1,3
R-HSA-157858,Gap junction trafficking and regulation,2/172,24/3769,0.08333333333333333,1.826065891472868,0.8876542807475827,0.30005336440808095,0.7452497055915802,0.6969892112408355,TUBB6/GJB3,2
R-HSA-8848021,Signaling by PTK6,2/172,24/3769,0.08333333333333333,1.826065891472868,0.8876542807475827,0.30005336440808095,0.7452497055915802,0.6969892112408355,CDK2/SOCS3,2
R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,2/172,24/3769,0.08333333333333333,1.826065891472868,0.8876542807475827,0.30005336440808095,0.7452497055915802,0.6969892112408355,CDK2/SOCS3,2
R-HSA-199418,Negative regulation of the PI3K/AKT network,4/172,61/3769,0.06557377049180328,1.4369043080442243,0.7521956774985319,0.30278120831803007,0.7452497055915802,0.6969892112408355,IL1RL1/RAC2/FGF2/BDNF,4
R-HSA-1181150,Signaling by NODAL,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CRIPTO,1
R-HSA-1482922,Acyl chain remodelling of PI,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,PLA2G5,1
R-HSA-176408,Regulation of APC/C activators between G1/S and early anaphase,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-180786,Extension of Telomeres,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-181431,Acetylcholine binding and downstream events,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CHRNB3,1
R-HSA-1839130,Signaling by activated point mutants of FGFR3,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-190239,FGFR3 ligand binding and activation,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-190372,FGFR3c ligand binding and activation,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-2033514,FGFR3 mutant receptor activation,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-210744,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,HES1,1
R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,MYC,1
R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-400451,Free fatty acids regulate insulin secretion,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CD36,1
R-HSA-425381,Bicarbonate transporters,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,SLC4A5,1
R-HSA-445144,Signal transduction by L1,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,ITGB3,1
R-HSA-5357956,TNFR1-induced NF-kappa-B signaling pathway,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,TNFRSF1A,1
R-HSA-5576890,Phase 3 - rapid repolarisation,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,KCNE4,1
R-HSA-5627117,RHO GTPases Activate ROCKs,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,LIMK2,1
R-HSA-5654227,Phospholipase C-mediated cascade; FGFR3,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5676594,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,TNFRSF12A,1
R-HSA-622327,Postsynaptic nicotinic acetylcholine receptors,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CHRNB3,1
R-HSA-629594,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CHRNB3,1
R-HSA-6782135,Dual incision in TC-NER,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-6782210,Gap-filling DNA repair synthesis and ligation in TC-NER,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-6804757,Regulation of TP53 Degradation,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,RUNX1,1
R-HSA-8963889,Assembly of active LPL and LIPC lipase complexes,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,ANGPTL4,1
R-HSA-936964,"Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)",1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CD14,1
R-HSA-9668328,Sealing of the nuclear envelope (NE) by ESCRT-III,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-9671793,Diseases of hemostasis,1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,F12,1
R-HSA-9824878,"Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7",1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,CD14,1
R-HSA-9933387,"RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression",1/172,8/3769,0.125,2.739098837209302,1.0766314030305528,0.3120451844212663,0.7452497055915802,0.6969892112408355,HELZ2,1
R-HSA-9013404,RAC2 GTPase cycle,3/172,43/3769,0.06976744186046512,1.5287993510005409,0.7625233857929826,0.31270052857469194,0.7452497055915802,0.6969892112408355,RAC2/VANGL1/CYFIP1,3
R-HSA-597592,Post-translational protein modification,22/172,430/3769,0.05116279069767442,1.1211195240670633,0.5834311669902632,0.3144909127418779,0.7452497055915802,0.6969892112408355,PLAUR/CP/MSLN/STC2/CISH/SPP1/CDKN1A/IL6/GALNT5/MYC/THBS1/RAB20/ARSL/ADAMTS4/ALB/ADAMTS9/TNIP2/TUBB6/HIC1/SOCS3/LYPD8/H4C2,22
R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,2/172,25/3769,0.08,1.7530232558139534,0.8259617290517641,0.3171828922821621,0.7452497055915802,0.6969892112408355,XYLT1/CHST3,2
R-HSA-5654738,Signaling by FGFR2,2/172,25/3769,0.08,1.7530232558139534,0.8259617290517641,0.3171828922821621,0.7452497055915802,0.6969892112408355,FGF2/POLR2A,2
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,3/172,44/3769,0.06818181818181818,1.4940539112050737,0.7207538867762057,0.32541557168726076,0.7452497055915802,0.6969892112408355,RAC2/FGF2/BDNF,3
R-HSA-9818564,Epigenetic regulation of gene expression by MLL3 and MLL4 complexes,3/172,44/3769,0.06818181818181818,1.4940539112050737,0.7207538867762057,0.32541557168726076,0.7452497055915802,0.6969892112408355,CD36/ANGPTL4/H4C2,3
R-HSA-9841922,MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,3/172,44/3769,0.06818181818181818,1.4940539112050737,0.7207538867762057,0.32541557168726076,0.7452497055915802,0.6969892112408355,CD36/ANGPTL4/H4C2,3
R-HSA-9851695,Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes,3/172,44/3769,0.06818181818181818,1.4940539112050737,0.7207538867762057,0.32541557168726076,0.7452497055915802,0.6969892112408355,CD36/ANGPTL4/H4C2,3
R-HSA-9833110,RSV-host interactions,2/172,26/3769,0.07692307692307693,1.685599284436494,0.7670021258794149,0.3342159598074147,0.7452497055915802,0.6969892112408355,TLR2/CD14,2
R-HSA-9909396,Circadian clock,2/172,26/3769,0.07692307692307693,1.685599284436494,0.7670021258794149,0.3342159598074147,0.7452497055915802,0.6969892112408355,HELZ2/LOC102724428,2
R-HSA-112409,RAF-independent MAPK1/3 activation,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,IL6,1
R-HSA-140875,Common Pathway of Fibrin Clot Formation,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,THBD,1
R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-190872,Transport of connexons to the plasma membrane,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-196757,Metabolism of folate and pterines,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,MTHFD2,1
R-HSA-2033519,Activated point mutants of FGFR2,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-2142845,Hyaluronan metabolism,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,CD44,1
R-HSA-2214320,Anchoring fibril formation,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,COL4A1,1
R-HSA-389977,Post-chaperonin tubulin folding pathway,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,TUBB6,1
R-HSA-453276,Regulation of mitotic cell cycle,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-4641262,Disassembly of the destruction complex and recruitment of AXIN to the membrane,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,WNT8A,1
R-HSA-5218921,VEGFR2 mediated cell proliferation,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,VEGFA,1
R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5654720,PI-3K cascade:FGFR4,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-6781827,Transcription-Coupled Nucleotide Excision Repair (TC-NER),1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-6806003,Regulation of TP53 Expression and Degradation,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-68949,Orc1 removal from chromatin,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,CDK2,1
R-HSA-74259,Purine catabolism,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,PNP,1
R-HSA-8941856,RUNX3 regulates NOTCH signaling,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,HES1,1
R-HSA-8963743,Digestion and absorption,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,SLC2A5,1
R-HSA-9635486,Infection with Mycobacterium tuberculosis,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,TLR2,1
R-HSA-9674555,Signaling by CSF3 (G-CSF),1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,SOCS3,1
R-HSA-9830364,Formation of the nephric duct,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-9840310,Glycosphingolipid catabolism,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,ARSL,1
R-HSA-9861718,Regulation of pyruvate metabolism,1/172,9/3769,0.1111111111111111,2.4347545219638245,0.9422244855937979,0.34350709037168947,0.7452497055915802,0.6969892112408355,PDK1,1
R-HSA-162587,HIV Life Cycle,2/172,27/3769,0.07407407407407407,1.623169681309216,0.7105354618055244,0.35112579584226333,0.7452497055915802,0.6969892112408355,POLR2A/NELFE,2
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,2/172,27/3769,0.07407407407407407,1.623169681309216,0.7105354618055244,0.35112579584226333,0.7452497055915802,0.6969892112408355,PLK4/TUBB6,2
R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,2/172,27/3769,0.07407407407407407,1.623169681309216,0.7105354618055244,0.35112579584226333,0.7452497055915802,0.6969892112408355,TNFRSF12A/TNFRSF1A,2
R-HSA-5693607,Processing of DNA double-strand break ends,2/172,27/3769,0.07407407407407407,1.623169681309216,0.7105354618055244,0.35112579584226333,0.7452497055915802,0.6969892112408355,CDK2/H4C2,2
R-HSA-6809371,Formation of the cornified envelope,2/172,27/3769,0.07407407407407407,1.623169681309216,0.7105354618055244,0.35112579584226333,0.7452497055915802,0.6969892112408355,DSC2/SPINK9,2
R-HSA-917937,Iron uptake and transport,2/172,27/3769,0.07407407407407407,1.623169681309216,0.7105354618055244,0.35112579584226333,0.7452497055915802,0.6969892112408355,CP/STEAP4,2
R-HSA-416476,G alpha (q) signalling events,7/172,128/3769,0.0546875,1.1983557412790697,0.49921643241615593,0.3670006401858458,0.7452497055915802,0.6969892112408355,EDN1/EDN3/HCRTR2/RGS16/FPR2/GPR4/OXTR,7
R-HSA-419037,NCAM1 interactions,2/172,28/3769,0.07142857142857142,1.5651993355481728,0.656351157983604,0.367888245237331,0.7452497055915802,0.6969892112408355,GDNF/COL4A1,2
R-HSA-5619102,SLC transporter disorders,2/172,28/3769,0.07142857142857142,1.5651993355481728,0.656351157983604,0.367888245237331,0.7452497055915802,0.6969892112408355,CP/SLC12A1,2
R-HSA-1234174,Cellular response to hypoxia,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,VEGFA,1
R-HSA-140837,Intrinsic Pathway of Fibrin Clot Formation,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,F12,1
R-HSA-167161,HIV Transcription Initiation,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-167162,RNA Polymerase II HIV Promoter Escape,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-190241,FGFR2 ligand binding and activation,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-190242,FGFR1 ligand binding and activation,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-201451,Signaling by BMP,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,INHA,1
R-HSA-2022870,Chondroitin sulfate biosynthesis,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,CHST3,1
R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,MYC,1
R-HSA-2243919,Crosslinking of collagen fibrils,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,COL4A1,1
R-HSA-354192,Integrin signaling,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,ITGB3,1
R-HSA-416572,Sema4D induced cell migration and growth-cone collapse,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,LIMK2,1
R-HSA-5601884,PIWI-interacting RNA (piRNA) biogenesis,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-5654710,PI-3K cascade:FGFR3,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5654712,FRS-mediated FGFR4 signaling,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5654719,SHC-mediated cascade:FGFR4,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5654733,Negative regulation of FGFR4 signaling,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,FGF2,1
R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,CYFIP1,1
R-HSA-73776,RNA Polymerase II Promoter Escape,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-73779,RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-75953,RNA Polymerase II Transcription Initiation,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-76042,RNA Polymerase II Transcription Initiation And Promoter Clearance,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,POLR2A,1
R-HSA-8978934,Metabolism of cofactors,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,NOS3,1
R-HSA-9006115,Signaling by NTRK2 (TRKB),1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,BDNF,1
R-HSA-9830674,Formation of the ureteric bud,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,GDNF,1
R-HSA-9834899,Specification of the neural plate border,1/172,10/3769,0.1,2.1912790697674422,0.8247585002693254,0.3735381490036229,0.7452497055915802,0.6969892112408355,ZIC1,1
R-HSA-9917777,Epigenetic regulation by WDR5-containing histone modifying complexes,3/172,48/3769,0.0625,1.369549418604651,0.5633947019368737,0.3761542476444718,0.7486386977509487,0.7001587408016484,CD36/ANGPTL4/H4C2,3
R-HSA-383280,Nuclear Receptor transcription pathway,2/172,29/3769,0.06896551724137931,1.511226944667201,0.6042635322982995,0.3844815881750878,0.7579623676561391,0.7088786333213374,NR4A3/NR4A1,2
R-HSA-5663205,Infectious disease,16/172,322/3769,0.049689440993788817,1.0888343203813375,0.3644496436421378,0.39816624505059073,0.7579623676561391,0.7088786333213374,VEGFA/IL1R1/IL1B/IL6/TLR2/FCGR2A/FCGR1A/RUNX1/CD14/TUBB6/POLR2A/FCGR3A/NELFE/CEBPD/CYFIP1/H4C2,16
R-HSA-6805567,Keratinization,2/172,30/3769,0.06666666666666667,1.4608527131782945,0.5541080952570642,0.40088637039764285,0.7579623676561391,0.7088786333213374,DSC2/SPINK9,2
R-HSA-9013409,RHOJ GTPase cycle,2/172,30/3769,0.06666666666666667,1.4608527131782945,0.5541080952570642,0.40088637039764285,0.7579623676561391,0.7088786333213374,SLC1A5/VANGL1,2
R-HSA-9820952,Respiratory Syncytial Virus Infection Pathway,2/172,30/3769,0.06666666666666667,1.4608527131782945,0.5541080952570642,0.40088637039764285,0.7579623676561391,0.7088786333213374,TLR2/CD14,2
R-HSA-983189,Kinesins,2/172,30/3769,0.06666666666666667,1.4608527131782945,0.5541080952570642,0.40088637039764285,0.7579623676561391,0.7088786333213374,TUBB6/KIF19,2
R-HSA-8951664,Neddylation,3/172,50/3769,0.06,1.3147674418604651,0.4899042072150343,0.40127573462662713,0.7579623676561391,0.7088786333213374,CISH/CDKN1A/SOCS3,3
R-HSA-9609646,HCMV Infection,3/172,50/3769,0.06,1.3147674418604651,0.4899042072150343,0.40127573462662713,0.7579623676561391,0.7088786333213374,TUBB6/CEBPD/H4C2,3
R-HSA-5668914,Diseases of metabolism,5/172,91/3769,0.054945054945054944,1.2039994888832097,0.43071834019509586,0.40191517793869524,0.7579623676561391,0.7088786333213374,CHST3/THBS1/ADAMTS4/ADAMTS9/PNP,5
R-HSA-1482801,Acyl chain remodelling of PS,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,PLA2G5,1
R-HSA-176187,Activation of ATR in response to replication stress,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,CDK2,1
R-HSA-3000480,Scavenging by Class A Receptors,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,COL4A1,1
R-HSA-5357786,TNFR1-induced proapoptotic signaling,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,TNFRSF1A,1
R-HSA-5576893,Phase 2 - plateau phase,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,KCNE4,1
R-HSA-5654689,PI-3K cascade:FGFR1,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,FGF2,1
R-HSA-5654695,PI-3K cascade:FGFR2,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,FGF2,1
R-HSA-5654704,SHC-mediated cascade:FGFR3,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,FGF2,1
R-HSA-5654706,FRS-mediated FGFR3 signaling,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,FGF2,1
R-HSA-5654732,Negative regulation of FGFR3 signaling,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,FGF2,1
R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,ITGB3,1
R-HSA-6803204,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,BBC3,1
R-HSA-69052,Switching of origins to a post-replicative state,1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,CDK2,1
R-HSA-9860927,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1/172,11/3769,0.09090909090909091,1.9920718816067653,0.7204611166273919,0.40220307009204437,0.7579623676561391,0.7088786333213374,ITGB3,1
R-HSA-5578749,Transcriptional regulation by small RNAs,2/172,31/3769,0.06451612903225806,1.413728432108027,0.5057385014447344,0.41708524371402833,0.7703822882347159,0.7204942711173491,POLR2A/H4C2,2
R-HSA-912446,Meiotic recombination,2/172,31/3769,0.06451612903225806,1.413728432108027,0.5057385014447344,0.41708524371402833,0.7703822882347159,0.7204942711173491,CDK2/H4C2,2
R-HSA-8939211,ESR-mediated signaling,5/172,93/3769,0.053763440860215055,1.178107026756689,0.3802631384804112,0.42030883858275514,0.7703822882347159,0.7204942711173491,MYC/RUNX1/NOS3/POLR2A/H4C2,5
R-HSA-382551,Transport of small molecules,16/172,327/3769,0.04892966360856269,1.0721854775620512,0.29865358267432074,0.42313295764669673,0.7703822882347159,0.7204942711173491,SLC38A5/SLC11A1/CP/SLC12A1/SLCO4A1/SLC1A5/SLC27A6/STEAP4/SLC16A3/SLC5A12/RUNX1/ALB/TTYH1/ANGPTL4/SLC4A5/SLC22A6,16
R-HSA-9013149,RAC1 GTPase cycle,5/172,94/3769,0.05319148936170213,1.1655739732805543,0.3554485749192504,0.4294731128605209,0.7703822882347159,0.7204942711173491,SH3BP1/SLC1A5/ARAP3/VANGL1/CYFIP1,5
R-HSA-1482788,Acyl chain remodelling of PC,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,PLA2G5,1
R-HSA-1980145,Signaling by NOTCH2,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,HES1,1
R-HSA-201556,Signaling by ALK,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,MYC,1
R-HSA-210991,Basigin interactions,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,SLC16A3,1
R-HSA-400685,Sema4D in semaphorin signaling,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,LIMK2,1
R-HSA-420029,Tight junction interactions,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,CLDN5,1
R-HSA-5654688,SHC-mediated cascade:FGFR1,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,FGF2,1
R-HSA-5654693,FRS-mediated FGFR1 signaling,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,FGF2,1
R-HSA-5654699,SHC-mediated cascade:FGFR2,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,FGF2,1
R-HSA-5654700,FRS-mediated FGFR2 signaling,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,FGF2,1
R-HSA-5654727,Negative regulation of FGFR2 signaling,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,FGF2,1
R-HSA-5655332,Signaling by FGFR3 in disease,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,FGF2,1
R-HSA-68962,Activation of the pre-replicative complex,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,CDK2,1
R-HSA-72163,mRNA Splicing - Major Pathway,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,POLR2A,1
R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,HES1,1
R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,BCL2A1,1
R-HSA-9931509,"Expression of BMAL (ARNTL), CLOCK, and NPAS2",1/172,12/3769,0.08333333333333333,1.826065891472868,0.6266631645225089,0.4295636533661712,0.7703822882347159,0.7204942711173491,HELZ2,1
R-HSA-170834,Signaling by TGF-beta Receptor Complex,2/172,32/3769,0.0625,1.369549418604651,0.459024023302964,0.43306281621071785,0.7749545132191793,0.7247704103249548,MYC/ITGB3,2
R-HSA-190236,Signaling by FGFR,2/172,33/3769,0.06060606060606061,1.3280479210711769,0.41384744434911264,0.4488055116198534,0.7762713937525457,0.7260020129909645,FGF2/POLR2A,2
R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),2/172,33/3769,0.06060606060606061,1.3280479210711769,0.41384744434911264,0.4488055116198534,0.7762713937525457,0.7260020129909645,CDK2/H4C2,2
R-HSA-373080,Class B/2 (Secretin family receptors),3/172,54/3769,0.05555555555555555,1.2173772609819122,0.3517880111160595,0.450591470926614,0.7762713937525457,0.7260020129909645,WNT8A/ADGRE2/ADM,3
R-HSA-195258,RHO GTPase Effectors,6/172,118/3769,0.05084745762711865,1.1142096964919197,0.27560526904703136,0.4537663442151195,0.7762713937525457,0.7260020129909645,RAC2/S100A9/TUBB6/LIMK2/CYFIP1/H4C2,6
R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian expression",1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,HELZ2,1
R-HSA-1482839,Acyl chain remodelling of PE,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,PLA2G5,1
R-HSA-182971,EGFR downregulation,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,PTPRK,1
R-HSA-1839124,FGFR1 mutant receptor activation,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,FGF2,1
R-HSA-1971475,A tetrasaccharide linker sequence is required for GAG synthesis,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,XYLT1,1
R-HSA-3238698,WNT ligand biogenesis and trafficking,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,WNT8A,1
R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,ZFP36,1
R-HSA-5213460,RIPK1-mediated regulated necrosis,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,TNFRSF10B,1
R-HSA-5626467,RHO GTPases activate IQGAPs,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,TUBB6,1
R-HSA-5654716,Downstream signaling of activated FGFR4,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,FGF2,1
R-HSA-5654726,Negative regulation of FGFR1 signaling,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,FGF2,1
R-HSA-5674135,MAP2K and MAPK activation,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,ITGB3,1
R-HSA-5675482,Regulation of necroptotic cell death,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,TNFRSF10B,1
R-HSA-70268,Pyruvate metabolism,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,PDK1,1
R-HSA-72172,mRNA Splicing,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,POLR2A,1
R-HSA-75876,Synthesis of very long-chain fatty acyl-CoAs,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,ACSL5,1
R-HSA-9013424,RHOV GTPase cycle,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,VANGL1,1
R-HSA-9749641,Aspirin ADME,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,ALB,1
R-HSA-9820960,Respiratory syncytial virus (RSV) attachment and entry,1/172,13/3769,0.07692307692307693,1.685599284436494,0.5414130150727046,0.4556789186366047,0.7762713937525457,0.7260020129909645,CD14,1
R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,2/172,34/3769,0.058823529411764705,1.2889876880984952,0.37010329168744105,0.46430143732880214,0.7874977264891142,0.7365013566880906,TUBB6/KIF19,2
R-HSA-109581,Apoptosis,3/172,56/3769,0.05357142857142857,1.1738995016611296,0.2866680735725948,0.47464174971196105,0.7874977264891142,0.7365013566880906,BBC3/TNFRSF10B/CD14,3
R-HSA-375165,NCAM signaling for neurite out-growth,2/172,35/3769,0.05714285714285714,1.2521594684385382,0.3276963448647403,0.47954026054231647,0.7874977264891142,0.7365013566880906,GDNF/COL4A1,2
R-HSA-5693538,Homology Directed Repair,2/172,35/3769,0.05714285714285714,1.2521594684385382,0.3276963448647403,0.47954026054231647,0.7874977264891142,0.7365013566880906,CDK2/H4C2,2
R-HSA-9610379,HCMV Late Events,2/172,35/3769,0.05714285714285714,1.2521594684385382,0.3276963448647403,0.47954026054231647,0.7874977264891142,0.7365013566880906,CEBPD/H4C2,2
R-HSA-9700206,Signaling by ALK in cancer,2/172,35/3769,0.05714285714285714,1.2521594684385382,0.3276963448647403,0.47954026054231647,0.7874977264891142,0.7365013566880906,CDKN1A/BCL2A1,2
R-HSA-9725370,Signaling by ALK fusions and activated point mutants,2/172,35/3769,0.05714285714285714,1.2521594684385382,0.3276963448647403,0.47954026054231647,0.7874977264891142,0.7365013566880906,CDKN1A/BCL2A1,2
R-HSA-977443,GABA receptor activation,2/172,35/3769,0.05714285714285714,1.2521594684385382,0.3276963448647403,0.47954026054231647,0.7874977264891142,0.7365013566880906,GABRA6/KCNJ16,2
R-HSA-114452,Activation of BH3-only proteins,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,BBC3,1
R-HSA-168638,NOD1/2 Signaling Pathway,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,CASP4,1
R-HSA-5654708,Downstream signaling of activated FGFR3,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,FGF2,1
R-HSA-5696398,Nucleotide Excision Repair,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,POLR2A,1
R-HSA-6807505,RNA polymerase II transcribes snRNA genes,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,POLR2A,1
R-HSA-75105,Fatty acyl-CoA biosynthesis,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,ACSL5,1
R-HSA-8940973,RUNX2 regulates osteoblast differentiation,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,HES1,1
R-HSA-9020591,Interleukin-12 signaling,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,IL12A,1
R-HSA-9619483,Activation of AMPK downstream of NMDARs,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,TUBB6,1
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,IL1B,1
R-HSA-9664424,Cell recruitment (pro-inflammatory response),1/172,14/3769,0.07142857142857142,1.5651993355481728,0.46324436096386407,0.48060523013673884,0.7874977264891142,0.7365013566880906,IL1B,1
R-HSA-1912408,Pre-NOTCH Transcription and Translation,2/172,36/3769,0.05555555555555555,1.2173772609819122,0.28654037125001075,0.49451309213478745,0.8023147659117159,0.7503588819478767,RUNX1/H4C2,2
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,2/172,36/3769,0.05555555555555555,1.2173772609819122,0.28654037125001075,0.49451309213478745,0.8023147659117159,0.7503588819478767,MYC/H4C2,2
R-HSA-1474244,Extracellular matrix organization,8/172,167/3769,0.04790419161676647,1.0497145244394932,0.1436875442378715,0.4970697837604098,0.8023147659117159,0.7503588819478767,CD44/SPP1/THBS1/FGF2/ADAMTS4/ADAMTS9/COL4A1/ITGB3,8
R-HSA-114604,GPVI-mediated activation cascade,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,RAC2,1
R-HSA-1266695,Interleukin-7 signaling,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,CISH,1
R-HSA-1483166,Synthesis of PA,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,PLA2G5,1
R-HSA-3928663,EPHA-mediated growth cone collapse,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,EFNA1,1
R-HSA-447115,Interleukin-12 family signaling,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,IL12A,1
R-HSA-5654696,Downstream signaling of activated FGFR2,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,FGF2,1
R-HSA-5655302,Signaling by FGFR1 in disease,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,FGF2,1
R-HSA-69273,Cyclin A/B1/B2 associated events during G2/M transition,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,CDK2,1
R-HSA-8854214,TBC/RABGAPs,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,TBC1D3,1
R-HSA-8943724,Regulation of PTEN gene transcription,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,EGR1,1
R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,EGR2,1
R-HSA-9692916,SARS-CoV-1 activates/modulates innate immune responses,1/172,15/3769,0.06666666666666667,1.4608527131782945,0.3910300159373717,0.5043964153342038,0.8023147659117159,0.7503588819478767,RUNX1,1
R-HSA-15869,Metabolism of nucleotides,2/172,37/3769,0.05405405405405406,1.184475172847266,0.24655704822261068,0.5092123777549558,0.8024566507850969,0.7504915787141321,TYMP/PNP,2
R-HSA-9679191,Potential therapeutics for SARS,2/172,37/3769,0.05405405405405406,1.184475172847266,0.24655704822261068,0.5092123777549558,0.8024566507850969,0.7504915787141321,VEGFA/IL1R1,2
R-HSA-9006931,Signaling by Nuclear Receptors,6/172,126/3769,0.047619047619047616,1.0434662236987817,0.10850682336632898,0.5183592267955532,0.8024566507850969,0.7504915787141321,MYC/PDK1/RUNX1/NOS3/POLR2A/H4C2,6
R-HSA-73887,Death Receptor Signaling,3/172,60/3769,0.05,1.0956395348837211,0.16328042251232788,0.52123385841744585,0.8024566507850969,0.7504915787141321,TNFRSF1A/TNFRSF10B/TNFRSF10D,3
R-HSA-1500620,Meiosis,2/172,38/3769,0.05263157894736842,1.1533047735618114,0.20767504029344558,0.5236317957690118,0.8024566507850969,0.7504915787141321,CDK2/H4C2,2
R-HSA-2980736,Peptide hormone metabolism,2/172,38/3769,0.05263157894736842,1.1533047735618114,0.20767504029344558,0.5236317957690118,0.8024566507850969,0.7504915787141321,INHA/ENPEP,2
R-HSA-9816359,Maternal to zygotic transition (MZT),2/172,38/3769,0.05263157894736842,1.1533047735618114,0.20767504029344558,0.5236317957690118,0.8024566507850969,0.7504915787141321,TEAD4/H4C2,2
R-HSA-163841,"Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation",1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ARSL,1
R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,IFI16,1
R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ITPKC,1
R-HSA-2426168,Activation of gene expression by SREBF (SREBP),1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,HELZ2,1
R-HSA-5357905,Regulation of TNFR1 signaling,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,TNFRSF1A,1
R-HSA-5620924,Intraflagellar transport,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,TUBB6,1
R-HSA-5654743,Signaling by FGFR4,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,FGF2,1
R-HSA-5669034,TNFs bind their physiological receptors,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,TNFRSF1A,1
R-HSA-5689896,Ovarian tumor domain proteases,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,TNIP2,1
R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ITGB3,1
R-HSA-6802949,Signaling by RAS mutants,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ITGB3,1
R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ITGB3,1
R-HSA-8941326,RUNX2 regulates bone development,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,HES1,1
R-HSA-9646399,Aggrephagy,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,TUBB6,1
R-HSA-9649948,Signaling downstream of RAS mutants,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ITGB3,1
R-HSA-9656223,Signaling by RAF1 mutants,1/172,16/3769,0.0625,1.369549418604651,0.3238863789179488,0.5271038784568773,0.8024566507850969,0.7504915787141321,ITGB3,1
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",2/172,39/3769,0.05128205128205128,1.1237328562909958,0.16982920541245283,0.5377661616503858,0.815645330681626,0.7628261929104474,ALB/ANGPTL4,2
R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,2/172,39/3769,0.05128205128205128,1.1237328562909958,0.16982920541245283,0.5377661616503858,0.815645330681626,0.7628261929104474,RUNX1/H4C2,2
R-HSA-392499,Metabolism of proteins,26/172,572/3769,0.045454545454545456,0.9960359408033826,-0.022506930983361127,0.543186768226313,0.8187546361593728,0.7657341475948727,PLAUR/CP/MSLN/STC2/CISH/SPP1/INHA/CDKN1A/IL6/GALNT5/MYC/THBS1/ENPEP/RAB20/PDK1/ARSL/ADAMTS4/ALB/ADAMTS9/TNIP2/TUBB6/HIC1/SOCS3/LYPD8/MRPL12/H4C2,26
R-HSA-1660662,Glycosphingolipid metabolism,1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,ARSL,1
R-HSA-3214841,PKMTs methylate histone lysines,1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-3214842,HDMs demethylate histones,1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-5654741,Signaling by FGFR3,1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,FGF2,1
R-HSA-76009,Platelet Aggregation (Plug Formation),1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,ITGB3,1
R-HSA-9013420,RHOU GTPase cycle,1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,VANGL1,1
R-HSA-9707616,Heme signaling,1/172,17/3769,0.058823529411764705,1.2889876880984952,0.2611089979578184,0.5487767089672471,0.8187546361593728,0.7657341475948727,HELZ2,1
R-HSA-211000,Gene Silencing by RNA,2/172,40/3769,0.05,1.0956395348837211,0.13295990954036593,0.5516113384457151,0.8187546361593728,0.7657341475948727,POLR2A/H4C2,2
R-HSA-9013408,RHOG GTPase cycle,2/172,40/3769,0.05,1.0956395348837211,0.13295990954036593,0.5516113384457151,0.8187546361593728,0.7657341475948727,VANGL1/CYFIP1,2
R-HSA-9748784,Drug ADME,2/172,40/3769,0.05,1.0956395348837211,0.13295990954036593,0.5516113384457151,0.8187546361593728,0.7657341475948727,ALB/PNP,2
R-HSA-1912422,Pre-NOTCH Expression and Processing,2/172,41/3769,0.04878048780487805,1.0689166193987523,0.09701243238629513,0.5651641529665742,0.8187546361593728,0.7657341475948727,RUNX1/H4C2,2
R-HSA-9734767,Developmental Cell Lineages,3/172,64/3769,0.046875,1.0271620639534884,0.047919039003472885,0.565518148694711,0.8187546361593728,0.7657341475948727,FGF2/HHEX/GJB3,3
R-HSA-109704,PI3K Cascade,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,FGF2,1
R-HSA-1655829,Regulation of cholesterol biosynthesis by SREBP (SREBF),1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,HELZ2,1
R-HSA-194068,Bile acid and bile salt metabolism,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,ALB,1
R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,HELZ2,1
R-HSA-380259,Loss of Nlp from mitotic centrosomes,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,PLK4,1
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,PLK4,1
R-HSA-392154,Nitric oxide stimulates guanylate cyclase,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,NOS3,1
R-HSA-5654687,Downstream signaling of activated FGFR1,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,FGF2,1
R-HSA-5687128,MAPK6/MAPK4 signaling,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,MYC,1
R-HSA-75893,TNF signaling,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,TNFRSF1A,1
R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,1/172,18/3769,0.05555555555555555,1.2173772609819122,0.2021279094757313,0.5694617852086206,0.8187546361593728,0.7657341475948727,TUBB6,1
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,3/172,65/3769,0.046153846153846156,1.0113595706618963,0.02019912507203377,0.5761963378249582,0.8187546361593728,0.7657341475948727,SIGLEC9/FCGR1A/FCGR3A,3
R-HSA-69002,DNA Replication Pre-Initiation,2/172,42/3769,0.047619047619047616,1.0434662236987817,0.06193645026194869,0.5784223173755998,0.8187546361593728,0.7657341475948727,CDK2/H4C2,2
R-HSA-1630316,Glycosaminoglycan metabolism,3/172,66/3769,0.045454545454545456,0.9960359408033826,-0.007103701348336287,0.5867108434105226,0.8187546361593728,0.7657341475948727,CD44/XYLT1/CHST3,3
R-HSA-73894,DNA Repair,3/172,66/3769,0.045454545454545456,0.9960359408033826,-0.007103701348336287,0.5867108434105226,0.8187546361593728,0.7657341475948727,CDK2/POLR2A/H4C2,3
R-HSA-1296041,Activation of G protein gated Potassium channels,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,KCNJ16,1
R-HSA-1296059,G protein gated Potassium channels,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,KCNJ16,1
R-HSA-186712,Regulation of beta-cell development,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,HES1,1
R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,ITGB3,1
R-HSA-2995410,Nuclear Envelope (NE) Reassembly,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,TUBB6,1
R-HSA-3000157,Laminin interactions,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,COL4A1,1
R-HSA-381119,Unfolded Protein Response (UPR),1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,CCL2,1
R-HSA-3928662,EPHB-mediated forward signaling,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,LIMK2,1
R-HSA-4551638,SUMOylation of chromatin organization proteins,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-5362517,Signaling by Retinoic Acid,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,PDK1,1
R-HSA-69239,Synthesis of DNA,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,CDK2,1
R-HSA-72203,Processing of Capped Intron-Containing Pre-mRNA,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,POLR2A,1
R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,TUBB6,1
R-HSA-9013694,Signaling by NOTCH4,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,HES1,1
R-HSA-917977,Transferrin endocytosis and recycling,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,STEAP4,1
R-HSA-9696264,RND3 GTPase cycle,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,VANGL1,1
R-HSA-977606,Regulation of Complement cascade,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,CR2,1
R-HSA-9821993,Replacement of protamines by nucleosomes in the male pronucleus,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-997272,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,1/172,19/3769,0.05263157894736842,1.1533047735618114,0.14647594083601087,0.5892038734368575,0.8187546361593728,0.7657341475948727,KCNJ16,1
R-HSA-162906,HIV Infection,2/172,43/3769,0.046511627906976744,1.0191995673336938,0.0276855844496557,0.5913843558536926,0.8187546361593728,0.7657341475948727,POLR2A/NELFE,2
R-HSA-3000178,ECM proteoglycans,2/172,43/3769,0.046511627906976744,1.0191995673336938,0.0276855844496557,0.5913843558536926,0.8187546361593728,0.7657341475948727,COL4A1/ITGB3,2
R-HSA-9824446,Viral Infection Pathways,10/172,229/3769,0.043668122270742356,0.9568904234792323,-0.14717678725867273,0.6064216352573785,0.8187546361593728,0.7657341475948727,VEGFA/IL1R1/TLR2/RUNX1/CD14/TUBB6/POLR2A/NELFE/CEBPD/H4C2,10
R-HSA-110328,Recognition and association of DNA glycosylase with site containing an affected pyrimidine,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-110329,Cleavage of the damaged pyrimidine,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-110330,Recognition and association of DNA glycosylase with site containing an affected purine,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-110331,Cleavage of the damaged purine,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-112399,IRS-mediated signalling,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,FGF2,1
R-HSA-171306,Packaging Of Telomere Ends,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,CHST3,1
R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,TUBB6,1
R-HSA-73927,Depurination,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-73928,Depyrimidination,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-73929,"Base-Excision Repair, AP Site Formation",1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,H4C2,1
R-HSA-8853659,RET signaling,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,GDNF,1
R-HSA-8854518,AURKA Activation by TPX2,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,PLK4,1
R-HSA-9035034,RHOF GTPase cycle,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,VANGL1,1
R-HSA-9696270,RND2 GTPase cycle,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,VANGL1,1
R-HSA-9696273,RND1 GTPase cycle,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,VANGL1,1
R-HSA-9725554,Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,GJB3,1
R-HSA-9833482,PKR-mediated signaling,1/172,20/3769,0.05,1.0956395348837211,0.09376573982229529,0.6080457224418871,0.8187546361593728,0.7657341475948727,TUBB6,1
R-HSA-166166,MyD88-independent TLR4 cascade,2/172,45/3769,0.044444444444444446,0.9739018087855298,-0.03850891488306825,0.61641780504934085,0.8218904067324544,0.7686668535616994,TNIP2/CD14,2
R-HSA-5619115,Disorders of transmembrane transporters,2/172,45/3769,0.044444444444444446,0.9739018087855298,-0.03850891488306825,0.61641780504934085,0.8218904067324544,0.7686668535616994,CP/SLC12A1,2
R-HSA-5693532,DNA Double-Strand Break Repair,2/172,45/3769,0.044444444444444446,0.9739018087855298,-0.03850891488306825,0.61641780504934085,0.8218904067324544,0.7686668535616994,CDK2/H4C2,2
R-HSA-937061,TRIF (TICAM1)-mediated TLR4 signaling,2/172,45/3769,0.044444444444444446,0.9739018087855298,-0.03850891488306825,0.61641780504934085,0.8218904067324544,0.7686668535616994,TNIP2/CD14,2
R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,2/172,45/3769,0.044444444444444446,0.9739018087855298,-0.03850891488306825,0.61641780504934085,0.8218904067324544,0.7686668535616994,TNIP2/CD14,2
R-HSA-975155,MyD88 dependent cascade initiated on endosome,2/172,45/3769,0.044444444444444446,0.9739018087855298,-0.03850891488306825,0.61641780504934085,0.8218904067324544,0.7686668535616994,TNIP2/CD14,2
R-HSA-5683057,MAPK family signaling cascades,5/172,116/3769,0.04310344827586207,0.9445168404170009,-0.13271340589780034,0.6177100457220541,0.8222698161650835,0.769021693394847,IL6/MYC/FGF2/GDNF/ITGB3,5
R-HSA-177929,Signaling by EGFR,1/172,21/3769,0.047619047619047616,1.0434662236987817,0.04367281828572484,0.6260281539542891,0.8245138574140723,0.7711204161831816,PTPRK,1
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,1/172,21/3769,0.047619047619047616,1.0434662236987817,0.04367281828572484,0.6260281539542891,0.8245138574140723,0.7711204161831816,PLK4,1
R-HSA-5607764,CLEC7A (Dectin-1) signaling,1/172,21/3769,0.047619047619047616,1.0434662236987817,0.04367281828572484,0.6260281539542891,0.8245138574140723,0.7711204161831816,IL1B,1
R-HSA-212165,Epigenetic regulation of gene expression,3/172,70/3769,0.04285714285714286,0.9391196013289037,-0.11241746652553009,0.6270851762909888,0.8245138574140723,0.7711204161831816,CD36/ANGPTL4/H4C2,3
R-HSA-69620,Cell Cycle Checkpoints,3/172,70/3769,0.04285714285714286,0.9391196013289037,-0.11241746652553009,0.6270851762909888,0.8245138574140723,0.7711204161831816,CDK2/CDKN1A/H4C2,3
R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,2/172,46/3769,0.043478260869565216,0.9527300303336704,-0.07052891014989116,0.6284897295484718,0.8245138574140723,0.7711204161831816,TNIP2/CD14,2
R-HSA-69481,G2/M Checkpoints,2/172,46/3769,0.043478260869565216,0.9527300303336704,-0.07052891014989116,0.6284897295484718,0.8245138574140723,0.7711204161831816,CDK2/H4C2,2
R-HSA-8856688,Golgi-to-ER retrograde transport,2/172,46/3769,0.043478260869565216,0.9527300303336704,-0.07052891014989116,0.6284897295484718,0.8245138574140723,0.7711204161831816,TUBB6/KIF19,2
R-HSA-9609690,HCMV Early Events,2/172,46/3769,0.043478260869565216,0.9527300303336704,-0.07052891014989116,0.6284897295484718,0.8245138574140723,0.7711204161831816,TUBB6/H4C2,2
R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,2/172,47/3769,0.0425531914893617,0.9324591786244433,-0.10187709062924295,0.6402664400644178,0.8278283306045364,0.7742202524358732,TNIP2/CD14,2
R-HSA-2682334,EPH-Ephrin signaling,2/172,47/3769,0.0425531914893617,0.9324591786244433,-0.10187709062924295,0.6402664400644178,0.8278283306045364,0.7742202524358732,EFNA1/LIMK2,2
R-HSA-9820448,Developmental Cell Lineages of the Exocrine Pancreas,2/172,47/3769,0.0425531914893617,0.9324591786244433,-0.10187709062924295,0.6402664400644178,0.8278283306045364,0.7742202524358732,FGF2/HHEX,2
R-HSA-1483249,Inositol phosphate metabolism,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,ITPKC,1
R-HSA-166658,Complement cascade,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,CR2,1
R-HSA-2129379,Molecules associated with elastic fibres,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,ITGB3,1
R-HSA-2428928,IRS-related events triggered by IGF1R,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,FGF2,1
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,TUBB6,1
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,PLK4,1
R-HSA-380287,Centrosome maturation,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,PLK4,1
R-HSA-5693571,Nonhomologous End-Joining (NHEJ),1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,H4C2,1
R-HSA-70171,Glycolysis,1/172,22/3769,0.045454545454545456,0.9960359408033826,-0.004077172410862496,0.6431901490236227,0.8278283306045364,0.7742202524358732,HK2,1
R-HSA-194315,Signaling by Rho GTPases,12/172,282/3769,0.0425531914893617,0.9324591786244433,-0.25781867370690653,0.6455127835366588,0.8291362753351236,0.7754434979591907,SH3BP1/SLC1A5/ARAP3/TRIP10/RAC2/S100A9/VANGL1/TUBB6/LIMK2/ARHGAP8/CYFIP1/H4C2,12
R-HSA-8980692,RHOA GTPase cycle,3/172,72/3769,0.041666666666666664,0.913032945736434,-0.16290924632757614,0.646238567540611,0.8291362753351236,0.7754434979591907,ARAP3/VANGL1/ARHGAP8,3
R-HSA-69306,DNA Replication,2/172,48/3769,0.041666666666666664,0.913032945736434,-0.1325851838710834,0.6517495788652851,0.8305682829109841,0.776782772330319,CDK2/H4C2,2
R-HSA-69278,"Cell Cycle, Mitotic",6/172,145/3769,0.041379310344827586,0.9067361668003208,-0.2504105484816014,0.6575630008483724,0.8305682829109841,0.776782772330319,CDK2/CDKN1A/MYC/PLK4/TUBB6/H4C2,6
R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,CASP4,1
R-HSA-2428924,IGF1R signaling cascade,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,FGF2,1
R-HSA-3214858,RMTs methylate histone arginines,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,H4C2,1
R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,CDK2,1
R-HSA-6807878,COPI-mediated anterograde transport,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,TUBB6,1
R-HSA-73884,Base Excision Repair,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,H4C2,1
R-HSA-74751,Insulin receptor signalling cascade,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,FGF2,1
R-HSA-8873719,RAB geranylgeranylation,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,RAB20,1
R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,IL6,1
R-HSA-975634,Retinoid metabolism and transport,1/172,23/3769,0.043478260869565216,0.9527300303336704,-0.04971813241868643,0.6595689305469579,0.8305682829109841,0.776782772330319,BCO1,1
R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",12/172,287/3769,0.041811846689895474,0.9162142451989305,-0.3228837607844178,0.6698937713384754,0.8386046185212516,0.7842986950824399,SH3BP1/SLC1A5/ARAP3/TRIP10/RAC2/S100A9/VANGL1/TUBB6/LIMK2/ARHGAP8/CYFIP1/H4C2,12
R-HSA-109606,Intrinsic Pathway for Apoptosis,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,BBC3,1
R-HSA-1296065,Inwardly rectifying K+ channels,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,KCNJ16,1
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,FGF2,1
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,PLK4,1
R-HSA-5654736,Signaling by FGFR1,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,FGF2,1
R-HSA-606279,Deposition of new CENPA-containing nucleosomes at the centromere,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,H4C2,1
R-HSA-6807070,PTEN Regulation,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,EGR1,1
R-HSA-774815,Nucleosome assembly,1/172,24/3769,0.041666666666666664,0.913032945736434,-0.09345099319307398,0.6752000421182136,0.8386046185212516,0.7842986950824399,H4C2,1
R-HSA-196854,Metabolism of vitamins and cofactors,3/172,76/3769,0.039473684210526314,0.8649785801713585,-0.25999755532461166,0.6824426693472064,0.8436146358717224,0.7889842763248177,MTHFD2/BCO1/NOS3,3
R-HSA-201681,TCF dependent signaling in response to WNT,3/172,76/3769,0.039473684210526314,0.8649785801713585,-0.25999755532461166,0.6824426693472064,0.8436146358717224,0.7889842763248177,WNT8A/MYC/H4C2,3
R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,2/172,51/3769,0.0392156862745098,0.8593251253989969,-0.2211548070181508,0.6844606679071517,0.8436146358717224,0.7889842763248177,HIC1/H4C2,2
R-HSA-68877,Mitotic Prometaphase,2/172,51/3769,0.0392156862745098,0.8593251253989969,-0.2211548070181508,0.6844606679071517,0.8436146358717224,0.7889842763248177,PLK4/TUBB6,2
R-HSA-9012999,RHO GTPase cycle,8/172,197/3769,0.04060913705583756,0.8898595207177429,-0.347195271303462,0.6866797796828363,0.8436146358717224,0.7889842763248177,SH3BP1/SLC1A5/ARAP3/TRIP10/RAC2/VANGL1/ARHGAP8/CYFIP1,8
R-HSA-427359,SIRT1 negatively regulates rRNA expression,1/172,25/3769,0.04,0.8765116279069767,-0.13544956087908802,0.6901174233613823,0.8436146358717224,0.7889842763248177,H4C2,1
R-HSA-437239,Recycling pathway of L1,1/172,25/3769,0.04,0.8765116279069767,-0.13544956087908802,0.6901174233613823,0.8436146358717224,0.7889842763248177,TUBB6,1
R-HSA-70326,Glucose metabolism,1/172,25/3769,0.04,0.8765116279069767,-0.13544956087908802,0.6901174233613823,0.8436146358717224,0.7889842763248177,HK2,1
R-HSA-73728,RNA Polymerase I Promoter Opening,1/172,25/3769,0.04,0.8765116279069767,-0.13544956087908802,0.6901174233613823,0.8436146358717224,0.7889842763248177,H4C2,1
R-HSA-9843970,Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex,1/172,25/3769,0.04,0.8765116279069767,-0.13544956087908802,0.6901174233613823,0.8436146358717224,0.7889842763248177,H4C2,1
R-HSA-1640170,Cell Cycle,7/172,174/3769,0.040229885057471264,0.8815490510558673,-0.3497946579905511,0.6906060989734197,0.8436146358717224,0.7889842763248177,CDK2/CDKN1A/MYC/PLK4/TUBB6/POLR2A/H4C2,7
R-HSA-5684996,MAPK1/MAPK3 signaling,4/172,102/3769,0.0392156862745098,0.8593251253989969,-0.3149275243496649,0.6929265021520209,0.8451838950015681,0.7904519141849029,IL6/FGF2/GDNF/ITGB3,4
R-HSA-2990846,SUMOylation,2/172,52/3769,0.038461538461538464,0.842799642218247,-0.24957919121917277,0.694794547444908,0.846197538380664,0.7913999165711835,HIC1/H4C2,2
R-HSA-6806667,Metabolism of fat-soluble vitamins,1/172,26/3769,0.038461538461538464,0.842799642218247,-0.1758651319286459,0.7043534819035411,0.852748699131762,0.7975268406482551,BCO1,1
R-HSA-913709,O-linked glycosylation of mucins,1/172,26/3769,0.038461538461538464,0.842799642218247,-0.1758651319286459,0.7043534819035411,0.852748699131762,0.7975268406482551,GALNT5,1
R-HSA-9821002,Chromatin modifications during the maternal to zygotic transition (MZT),1/172,26/3769,0.038461538461538464,0.842799642218247,-0.1758651319286459,0.7043534819035411,0.852748699131762,0.7975268406482551,H4C2,1
R-HSA-5617833,Cilium Assembly,2/172,54/3769,0.037037037037037035,0.811584840654608,-0.3049177907147617,0.7146282982676972,0.852748699131762,0.7975268406482551,PLK4/TUBB6,2
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,2/172,54/3769,0.037037037037037035,0.811584840654608,-0.3049177907147617,0.7146282982676972,0.852748699131762,0.7975268406482551,TUBB6/KIF19,2
R-HSA-1566948,Elastic fibre formation,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,ITGB3,1
R-HSA-1592230,Mitochondrial biogenesis,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,HELZ2,1
R-HSA-168273,Influenza Viral RNA Transcription and Replication,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,POLR2A,1
R-HSA-2142753,Arachidonate metabolism,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,ALOX12B,1
R-HSA-2299718,Condensation of Prophase Chromosomes,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,H4C2,1
R-HSA-427389,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,H4C2,1
R-HSA-450294,MAP kinase activation,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,TNIP2,1
R-HSA-5625886,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,H4C2,1
R-HSA-68616,Assembly of the ORC complex at the origin of replication,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,H4C2,1
R-HSA-9013405,RHOD GTPase cycle,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,VANGL1,1
R-HSA-977444,GABA B receptor activation,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,KCNJ16,1
R-HSA-991365,Activation of GABAB receptors,1/172,27/3769,0.037037037037037035,0.811584840654608,-0.21483017590871928,0.7179391621366672,0.852748699131762,0.7975268406482551,KCNJ16,1
R-HSA-1852241,Organelle biogenesis and maintenance,3/172,81/3769,0.037037037037037035,0.811584840654608,-0.3748110161195975,0.7237589775807799,0.8556925005783999,0.8002800089258769,HELZ2/PLK4/TUBB6,3
R-HSA-1221632,Meiotic synapsis,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,H4C2,1
R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,TUBB6,1
R-HSA-212300,PRC2 methylates histones and DNA,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,H4C2,1
R-HSA-5250924,B-WICH complex positively regulates rRNA expression,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,H4C2,1
R-HSA-5334118,DNA methylation,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,H4C2,1
R-HSA-6802952,Signaling by BRAF and RAF1 fusions,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,ITGB3,1
R-HSA-73772,RNA Polymerase I Promoter Escape,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,H4C2,1
R-HSA-8986944,Transcriptional Regulation by MECP2,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,BDNF,1
R-HSA-9710421,Defective pyroptosis,1/172,28/3769,0.03571428571428571,0.7825996677740864,-0.25246130139927747,0.7309040109107166,0.8556925005783999,0.8002800089258769,H4C2,1
R-HSA-1474165,Reproduction,2/172,56/3769,0.03571428571428571,0.7825996677740864,-0.35837787824538114,0.7333765392349422,0.8573571003090442,0.8018368133695266,CDK2/H4C2,2
R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,4/172,109/3769,0.03669724770642202,0.8041391081715383,-0.45370115572686703,0.7419393442153484,0.8590841530878353,0.8034520265591855,GABRA6/CHRNB3/KCNJ16/TUBB6,4
R-HSA-8957322,Metabolism of steroids,2/172,57/3769,0.03508771929824561,0.7688698490412076,-0.3844496754532777,0.7423543063850528,0.8590841530878353,0.8034520265591855,HELZ2/ALB,2
R-HSA-199977,ER to Golgi Anterograde Transport,1/172,29/3769,0.034482758620689655,0.7556134723336005,-0.28886166504769695,0.743276240294132,0.8590841530878353,0.8034520265591855,TUBB6,1
R-HSA-390466,Chaperonin-mediated protein folding,1/172,29/3769,0.034482758620689655,0.7556134723336005,-0.28886166504769695,0.743276240294132,0.8590841530878353,0.8034520265591855,TUBB6,1
R-HSA-4086400,PCP/CE pathway,1/172,29/3769,0.034482758620689655,0.7556134723336005,-0.28886166504769695,0.743276240294132,0.8590841530878353,0.8034520265591855,RAC2,1
R-HSA-448424,Interleukin-17 signaling,1/172,29/3769,0.034482758620689655,0.7556134723336005,-0.28886166504769695,0.743276240294132,0.8590841530878353,0.8034520265591855,TNIP2,1
R-HSA-5693565,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,1/172,29/3769,0.034482758620689655,0.7556134723336005,-0.28886166504769695,0.743276240294132,0.8590841530878353,0.8034520265591855,H4C2,1
R-HSA-9692914,SARS-CoV-1-host interactions,1/172,29/3769,0.034482758620689655,0.7556134723336005,-0.28886166504769695,0.743276240294132,0.8590841530878353,0.8034520265591855,RUNX1,1
R-HSA-418597,G alpha (z) signalling events,1/172,30/3769,0.03333333333333333,0.7304263565891472,-0.3241229438614704,0.7550827875319419,0.8685292886359889,0.8122855189126572,RGS16,1
R-HSA-5250913,Positive epigenetic regulation of rRNA expression,1/172,30/3769,0.03333333333333333,0.7304263565891472,-0.3241229438614704,0.7550827875319419,0.8685292886359889,0.8122855189126572,H4C2,1
R-HSA-5693606,DNA Double Strand Break Response,1/172,30/3769,0.03333333333333333,0.7304263565891472,-0.3241229438614704,0.7550827875319419,0.8685292886359889,0.8122855189126572,H4C2,1
R-HSA-71387,Metabolism of carbohydrates and carbohydrate derivatives,4/172,112/3769,0.03571428571428571,0.7825996677740864,-0.5106886269348333,0.7610596694473347,0.8685292886359889,0.8122855189126572,CD44/XYLT1/CHST3/HK2,4
R-HSA-1638091,Heparan sulfate/heparin (HS-GAG) metabolism,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,XYLT1,1
R-HSA-391251,Protein folding,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,TUBB6,1
R-HSA-3928665,EPH-ephrin mediated repulsion of cells,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,EFNA1,1
R-HSA-5610787,Hedgehog 'off' state,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,TUBB6,1
R-HSA-69473,G2/M DNA damage checkpoint,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,H4C2,1
R-HSA-73854,RNA Polymerase I Promoter Clearance,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,H4C2,1
R-HSA-73864,RNA Polymerase I Transcription,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,H4C2,1
R-HSA-8948216,Collagen chain trimerization,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,COL4A1,1
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,TUBB6,1
R-HSA-9843940,Regulation of endogenous retroelements by KRAB-ZFP proteins,1/172,31/3769,0.03225806451612903,0.7068642160540135,-0.3583269618123842,0.7663493723258725,0.8685292886359889,0.8122855189126572,H4C2,1
R-HSA-8978868,Fatty acid metabolism,2/172,60/3769,0.03333333333333333,0.7304263565891472,-0.4602291139101282,0.767757452500225,0.8689182818865236,0.8126493219397958,ALOX12B/ACSL5,2
R-HSA-427413,NoRC negatively regulates rRNA expression,1/172,32/3769,0.03125,0.6847747093023255,-0.39154704052637285,0.7771005515553935,0.8758481354546976,0.8191304156406808,H4C2,1
R-HSA-5250941,Negative epigenetic regulation of rRNA expression,1/172,32/3769,0.03125,0.6847747093023255,-0.39154704052637285,0.7771005515553935,0.8758481354546976,0.8191304156406808,H4C2,1
R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,1/172,32/3769,0.03125,0.6847747093023255,-0.39154704052637285,0.7771005515553935,0.8758481354546976,0.8191304156406808,TLR2,1
R-HSA-5653656,Vesicle-mediated transport,8/172,216/3769,0.037037037037037035,0.811584840654608,-0.6235834284099823,0.7807727524743391,0.8787731945090493,0.8218660552361463,TRIP10/CD36/ALB/TUBB6/COL4A1/GJB3/KIF19/TBC1D3,8
R-HSA-6802957,Oncogenic MAPK signaling,1/172,33/3769,0.030303030303030304,0.6640239605355884,-0.4238491280202781,0.7873597715533792,0.8813245179527537,0.8242521613980217,ITGB3,1
R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,1/172,33/3769,0.030303030303030304,0.6640239605355884,-0.4238491280202781,0.7873597715533792,0.8813245179527537,0.8242521613980217,CHRNA10,1
R-HSA-9663891,Selective autophagy,1/172,33/3769,0.030303030303030304,0.6640239605355884,-0.4238491280202781,0.7873597715533792,0.8813245179527537,0.8242521613980217,TUBB6,1
R-HSA-9845323,Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),1/172,33/3769,0.030303030303030304,0.6640239605355884,-0.4238491280202781,0.7873597715533792,0.8813245179527537,0.8242521613980217,H4C2,1
R-HSA-168255,Influenza Infection,1/172,34/3769,0.029411764705882353,0.6444938440492476,-0.4552927475847279,0.7971494180450329,0.8849985375846896,0.8276882607699948,POLR2A,1
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,1/172,34/3769,0.029411764705882353,0.6444938440492476,-0.4552927475847279,0.7971494180450329,0.8849985375846896,0.8276882607699948,COL4A1,1
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,1/172,34/3769,0.029411764705882353,0.6444938440492476,-0.4552927475847279,0.7971494180450329,0.8849985375846896,0.8276882607699948,TUBB6,1
R-HSA-3214815,HDACs deacetylate histones,1/172,34/3769,0.029411764705882353,0.6444938440492476,-0.4552927475847279,0.7971494180450329,0.8849985375846896,0.8276882607699948,H4C2,1
R-HSA-373755,Semaphorin interactions,1/172,34/3769,0.029411764705882353,0.6444938440492476,-0.4552927475847279,0.7971494180450329,0.8849985375846896,0.8276882607699948,LIMK2,1
R-HSA-9824439,Bacterial Infection Pathways,1/172,34/3769,0.029411764705882353,0.6444938440492476,-0.4552927475847279,0.7971494180450329,0.8849985375846896,0.8276882607699948,TLR2,1
R-HSA-373760,L1CAM interactions,2/172,64/3769,0.03125,0.6847747093023255,-0.5561172753914739,0.798239858856867,0.8850050609065265,0.8276943616579355,TUBB6/ITGB3,2
R-HSA-372790,Signaling by GPCR,14/172,367/3769,0.03814713896457766,0.8359102718458906,-0.7234303498248515,0.8014761839953282,0.887387471017894,0.829922492889542,WNT8A/EDN1/CCL2/EDN3/ADGRE2/HCRTR2/RGS16/ADM/CXCR1/FPR2/FPR1/GPR4/OXTR/ACKR1,14
R-HSA-68886,M Phase,3/172,93/3769,0.03225806451612903,0.7068642160540135,-0.6258525294259906,0.8058246177499131,0.8905230648238325,0.832855033536221,PLK4/TUBB6/H4C2,3
R-HSA-1442490,Collagen degradation,1/172,35/3769,0.02857142857142857,0.6260797342192691,-0.4859317999278859,0.8064908638539364,0.8905230648238325,0.832855033536221,COL4A1,1
R-HSA-2467813,Separation of Sister Chromatids,1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,TUBB6,1
R-HSA-5621481,C-type lectin receptors (CLRs),1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,IL1B,1
R-HSA-5625740,RHO GTPases activate PKNs,1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,H4C2,1
R-HSA-68867,Assembly of the pre-replicative complex,1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,H4C2,1
R-HSA-74752,Signaling by Insulin receptor,1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,FGF2,1
R-HSA-9009391,Extra-nuclear estrogen signaling,1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,NOS3,1
R-HSA-948021,Transport to the Golgi and subsequent modification,1/172,36/3769,0.027777777777777776,0.6086886304909561,-0.5158152448282138,0.8154045144744836,0.8919170024278534,0.8341587032510238,TUBB6,1
R-HSA-9679506,SARS-CoV Infections,4/172,123/3769,0.032520325203252036,0.7126110795991681,-0.7085388956627501,0.8219102747912944,0.8940298389762692,0.8361347178248132,VEGFA/IL1R1/TLR2/RUNX1,4
R-HSA-3214847,HATs acetylate histones,1/172,37/3769,0.02702702702702703,0.592237586423633,-0.5449876832518523,0.8239098516055815,0.8940298389762692,0.8361347178248132,H4C2,1
R-HSA-428157,Sphingolipid metabolism,1/172,37/3769,0.02702702702702703,0.592237586423633,-0.5449876832518523,0.8239098516055815,0.8940298389762692,0.8361347178248132,ARSL,1
R-HSA-9007101,Rab regulation of trafficking,1/172,37/3769,0.02702702702702703,0.592237586423633,-0.5449876832518523,0.8239098516055815,0.8940298389762692,0.8361347178248132,TBC1D3,1
R-HSA-9013106,RHOC GTPase cycle,1/172,37/3769,0.02702702702702703,0.592237586423633,-0.5449876832518523,0.8239098516055815,0.8940298389762692,0.8361347178248132,VANGL1,1
R-HSA-9842860,Regulation of endogenous retroelements,1/172,37/3769,0.02702702702702703,0.592237586423633,-0.5449876832518523,0.8239098516055815,0.8940298389762692,0.8361347178248132,H4C2,1
R-HSA-438064,Post NMDA receptor activation events,1/172,38/3769,0.02631578947368421,0.5766523867809057,-0.5734898567784071,0.8320254747362996,0.8992487250130072,0.8410156419432794,TUBB6,1
R-HSA-5663220,RHO GTPases Activate Formins,1/172,38/3769,0.02631578947368421,0.5766523867809057,-0.5734898567784071,0.8320254747362996,0.8992487250130072,0.8410156419432794,TUBB6,1
R-HSA-9013026,RHOB GTPase cycle,1/172,38/3769,0.02631578947368421,0.5766523867809057,-0.5734898567784071,0.8320254747362996,0.8992487250130072,0.8410156419432794,VANGL1,1
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,1/172,39/3769,0.02564102564102564,0.5618664281454979,-0.6013590779604808,0.8397691408701395,0.9052201042933076,0.846600329737678,COL4A1,1
R-HSA-72766,Translation,1/172,39/3769,0.02564102564102564,0.5618664281454979,-0.6013590779604808,0.8397691408701395,0.9052201042933076,0.846600329737678,MRPL12,1
R-HSA-5688426,Deubiquitination,2/172,71/3769,0.028169014084507043,0.6172617097936456,-0.7118640891604624,0.8431742236577493,0.906901662420733,0.8481729943950354,MYC/TNIP2,2
R-HSA-5673001,RAF/MAP kinase cascade,3/172,100/3769,0.03,0.6573837209302326,-0.7592478834539444,0.8435519139428141,0.906901662420733,0.8481729943950354,FGF2/GDNF/ITGB3,3
R-HSA-1632852,Macroautophagy,1/172,40/3769,0.025,0.5478197674418606,-0.6286296027052858,0.8471578024707658,0.907192607370269,0.8484450984822559,TUBB6,1
R-HSA-9645723,Diseases of programmed cell death,1/172,40/3769,0.025,0.5478197674418606,-0.6286296027052858,0.8471578024707658,0.907192607370269,0.8484450984822559,H4C2,1
R-HSA-9678108,SARS-CoV-1 Infection,1/172,40/3769,0.025,0.5478197674418606,-0.6286296027052858,0.8471578024707658,0.907192607370269,0.8484450984822559,RUNX1,1
R-HSA-195721,Signaling by WNT,4/172,130/3769,0.03076923076923077,0.6742397137745976,-0.8264721772783314,0.8535931240308827,0.9111548199555952,0.8521507281576451,WNT8A/RAC2/MYC/H4C2,4
R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,1/172,41/3769,0.024390243902439025,0.5344583096993761,-0.6553329537535117,0.8542076437083705,0.9111548199555952,0.8521507281576451,MTHFD2,1
R-HSA-5689880,Ub-specific processing proteases,1/172,41/3769,0.024390243902439025,0.5344583096993761,-0.6553329537535117,0.8542076437083705,0.9111548199555952,0.8521507281576451,MYC,1
R-HSA-8953854,Metabolism of RNA,2/172,74/3769,0.02702702702702703,0.592237586423633,-0.7745782203836257,0.8595099091266833,0.9132376834295717,0.8540987106378216,ZFP36/POLR2A,2
R-HSA-5633007,Regulation of TP53 Activity,1/172,42/3769,0.023809523809523808,0.5217331118493909,-0.681498202723034,0.8609341150823406,0.9132376834295717,0.8540987106378216,CDK2,1
R-HSA-977225,Amyloid fiber formation,1/172,42/3769,0.023809523809523808,0.5217331118493909,-0.681498202723034,0.8609341150823406,0.9132376834295717,0.8540987106378216,H4C2,1
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,TUBB6,1
R-HSA-1428517,Aerobic respiration and respiratory electron transport,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,PDK1,1
R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,TNIP2,1
R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,TNIP2,1
R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,TNIP2,1
R-HSA-5358351,Signaling by Hedgehog,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,TUBB6,1
R-HSA-975871,MyD88 cascade initiated on plasma membrane,1/172,43/3769,0.023255813953488372,0.5095997836668469,-0.7071522168936711,0.8673519664925465,0.9132376834295717,0.8540987106378216,TNIP2,1
R-HSA-2555396,Mitotic Metaphase and Anaphase,1/172,44/3769,0.022727272727272728,0.4980179704016913,-0.7323198758659547,0.873475278828371,0.9137895224666035,0.854614813968379,TUBB6,1
R-HSA-2559580,Oxidative Stress Induced Senescence,1/172,44/3769,0.022727272727272728,0.4980179704016913,-0.7323198758659547,0.873475278828371,0.9137895224666035,0.854614813968379,H4C2,1
R-HSA-442755,Activation of NMDA receptors and postsynaptic events,1/172,44/3769,0.022727272727272728,0.4980179704016913,-0.7323198758659547,0.873475278828371,0.9137895224666035,0.854614813968379,TUBB6,1
R-HSA-68882,Mitotic Anaphase,1/172,44/3769,0.022727272727272728,0.4980179704016913,-0.7323198758659547,0.873475278828371,0.9137895224666035,0.854614813968379,TUBB6,1
R-HSA-9659379,Sensory processing of sound,1/172,44/3769,0.022727272727272728,0.4980179704016913,-0.7323198758659547,0.873475278828371,0.9137895224666035,0.854614813968379,CHRNA10,1
R-HSA-1280218,Adaptive Immune System,9/172,268/3769,0.033582089552238806,0.7358772995487678,-0.9809040376119259,0.8746240758532895,0.9138197770759081,0.8546431093653681,SIGLEC9/CD36/TLR2/FCGR1A/S100A9/CD14/TUBB6/SOCS3/FCGR3A,9
R-HSA-9013148,CDC42 GTPase cycle,2/172,78/3769,0.02564102564102564,0.5618664281454979,-0.8549313887961877,0.8788840582145561,0.9152080041064913,0.8559414383090893,ARAP3/VANGL1,2
R-HSA-422356,Regulation of insulin secretion,1/172,45/3769,0.022222222222222223,0.4869509043927649,-0.7570242623795231,0.8793174941415308,0.9152080041064913,0.8559414383090893,CD36,1
R-HSA-68875,Mitotic Prophase,1/172,45/3769,0.022222222222222223,0.4869509043927649,-0.7570242623795231,0.8793174941415308,0.9152080041064913,0.8559414383090893,H4C2,1
R-HSA-556833,Metabolism of lipids,9/172,271/3769,0.033210332103321034,0.7277310563803313,-1.0172373569580282,0.882556820745166,0.9174093830930642,0.8580002615356961,PLA2G5/HELZ2/CD36/HILPDA/ARSL/ALB/ANGPTL4/ALOX12B/ACSL5,9
R-HSA-9612973,Autophagy,1/172,46/3769,0.021739130434782608,0.4763650151668352,-0.7812868308850245,0.884891444465821,0.9186659270790203,0.8591754348971745,TUBB6,1
R-HSA-2672351,Stimuli-sensing channels,1/172,47/3769,0.02127659574468085,0.46622958931222164,-0.8051275568959392,0.8902093793441124,0.9230125203872881,0.863240553767781,TTYH1,1
R-HSA-1474290,Collagen formation,1/172,48/3769,0.020833333333333332,0.456516472868217,-0.8285650696790404,0.8952829921202576,0.9270950781346831,0.8670587353555793,COL4A1,1
R-HSA-2132295,MHC class II antigen presentation,1/172,49/3769,0.02040816326530612,0.44719981015662075,-0.8516167704550671,0.9001234450510063,0.9285723529224035,0.8684403455479134,TUBB6,1
R-HSA-2187338,Visual phototransduction,1/172,49/3769,0.02040816326530612,0.44719981015662075,-0.8516167704550671,0.9001234450510063,0.9285723529224035,0.8684403455479134,BCO1,1
R-HSA-418346,Platelet homeostasis,1/172,49/3769,0.02040816326530612,0.44719981015662075,-0.8516167704550671,0.9001234450510063,0.9285723529224035,0.8684403455479134,NOS3,1
R-HSA-112315,Transmission across Chemical Synapses,4/172,147/3769,0.027210884353741496,0.596266413542161,-1.091764015085129,0.9113075615378017,0.9389229421904624,0.8781206567183761,GABRA6/CHRNB3/KCNJ16/TUBB6,4
R-HSA-1483206,Glycerophospholipid biosynthesis,1/172,52/3769,0.019230769230769232,0.4213998211091235,-0.9186147329724179,0.913349997216945,0.9398406024325688,0.8789788915939272,PLA2G5,1
R-HSA-9705683,SARS-CoV-2-host interactions,1/172,54/3769,0.018518518518518517,0.405792420327304,-0.9616235925455829,0.9211847482123378,0.9467087588680952,0.8854022835131179,TLR2,1
R-HSA-418594,G alpha (i) signalling events,4/172,152/3769,0.02631578947368421,0.5766523867809057,-1.164914649498977,0.9239412118820056,0.9468812796775632,0.8855636323093824,RGS16/CXCR1/FPR2/FPR1,4
R-HSA-163685,Integration of energy metabolism,1/172,55/3769,0.01818181818181818,0.39841437632135307,-0.982669090874098,0.9248337989007571,0.9468812796775632,0.8855636323093824,CD36,1
R-HSA-3247509,Chromatin modifying enzymes,1/172,55/3769,0.01818181818181818,0.39841437632135307,-0.982669090874098,0.9248337989007571,0.9468812796775632,0.8855636323093824,H4C2,1
R-HSA-3858494,Beta-catenin independent WNT signaling,1/172,56/3769,0.017857142857142856,0.3912998338870432,-1.0034238300633571,0.9283148399855902,0.9492542724664681,0.8877829560606159,RAC2,1
R-HSA-4839726,Chromatin organization,1/172,58/3769,0.017241379310344827,0.37780673616680027,-1.0441028377526018,0.9348033124600201,0.9546927446400205,0.8928692464706074,H4C2,1
R-HSA-388396,GPCR downstream signalling,10/172,327/3769,0.03058103975535168,0.6701159234762819,-1.3648321608224987,0.9405308456936297,0.9593414626075023,0.8972169251682651,EDN1/EDN3/HCRTR2/RGS16/ADM/CXCR1/FPR2/FPR1/GPR4/OXTR,10
R-HSA-8856828,Clathrin-mediated endocytosis,1/172,61/3769,0.01639344262295082,0.3592260770110561,-1.1031875086873102,0.9434572034118909,0.9611249413034993,0.8988849102748155,TRIP10,1
R-HSA-9675108,Nervous system development,7/172,249/3769,0.028112449799196786,0.6160222284486784,-1.3708308744237272,0.9453516388190988,0.9618540365042201,0.899566791106243,EGR2/GDNF/EFNA1/TUBB6/LIMK2/COL4A1/ITGB3,7
R-HSA-446203,Asparagine N-linked glycosylation,1/172,63/3769,0.015873015873015872,0.3478220745662606,-1.1413875046438906,0.9485818262222218,0.9639386926492316,0.9015164501685925,TUBB6,1
R-HSA-199991,Membrane Trafficking,5/172,200/3769,0.025,0.5478197674418606,-1.4368212695969589,0.9569370789126366,0.971219721881482,0.9083259782818296,TRIP10/TUBB6/GJB3/KIF19/TBC1D3,5
R-HSA-422475,Axon guidance,6/172,234/3769,0.02564102564102564,0.5618664281454979,-1.513105477312357,0.9625259919822594,0.9756785210652469,0.9124960368579771,GDNF/EFNA1/TUBB6/LIMK2/COL4A1/ITGB3,6
R-HSA-1296071,Potassium Channels,1/172,71/3769,0.014084507042253521,0.3086308548968228,-1.285893989041888,0.9648564385819227,0.9768273621375297,0.9135704818752696,KCNJ16,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,1/172,74/3769,0.013513513513513514,0.2961187932118165,-1.3370802074021007,0.9695368520651262,0.9803495307126926,0.9168645636825362,SOCS3,1
R-HSA-418555,G alpha (s) signalling events,1/172,78/3769,0.01282051282051282,0.28093321407274896,-1.4031172350658083,0.974827107045066,0.9844788605801658,0.9207264885456915,ADM,1
R-HSA-5576891,Cardiac conduction,1/172,80/3769,0.0125,0.2739098837209303,-1.4352602019736969,0.9771188515046858,0.9855735263631935,0.9217502665290446,KCNE4,1
R-HSA-9694516,SARS-CoV-2 Infection,1/172,82/3769,0.012195121951219513,0.26722915484968807,-1.4668577193419081,0.9792030577075306,0.9864564136905493,0.9225759802962439,TLR2,1
R-HSA-1483257,Phospholipid metabolism,1/172,85/3769,0.011764705882352941,0.25779753761969904,-1.513287673571279,0.981980664876696,0.9880347996786484,0.9240521539822241,PLA2G5,1
R-HSA-983712,Ion channel transport,1/172,87/3769,0.011494252873563218,0.25187115744453353,-1.5436313287933385,0.9836241912108619,0.9884696305764327,0.9244588263259979,TTYH1,1
R-HSA-9709957,Sensory Perception,2/172,138/3769,0.014492753623188406,0.31757667677789014,-1.7857873066068821,0.9889698232548445,0.9926191583960062,0.9283396411727355,CHRNA10/BCO1,2
R-HSA-397014,Muscle contraction,1/172,109/3769,0.009174311926605505,0.20103477704288458,-1.8507596981570653,0.9943013030969532,0.9967443038416632,0.9321976525866947,KCNE4,1
R-HSA-112316,Neuronal System,4/172,235/3769,0.01702127659574468,0.37298367144977734,-2.170345928051266,0.9956661801942879,0.9968878564890048,0.9323319091260686,GABRA6/CHRNB3/KCNJ16/TUBB6,4
R-HSA-1430728,Metabolism,20/172,747/3769,0.02677376171352075,0.586687836617789,-2.7582949789076245,0.9987428965702455,0.9987428965702455,0.9340668214827502,TYMP/CD44/MTHFD2/ITPKC/XYLT1/CHST3/PLA2G5/HELZ2/CD36/HILPDA/BCO1/PDK1/ARSL/HK2/ALB/NOS3/ANGPTL4/ALOX12B/ACSL5/PNP,20
